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INTRODUCTION
Colorectal cancer (CRC) is the third most often diagnosed cancer in Europe, and is listed 
third of all cancer-related deaths.[1] People who suffer from CRC have a 20-40% chance of 
developing liver metastasis (colorectal liver metastasis; CRLM).[2-5] Both CRC and CRLM can 
be detected with (a combination of ) various techniques: CT-scan, MRI, ultra sound, PET, 
fine-needle aspiration, serum carcinoembryonic antigen (CEA), colonoscopy, laparoscopy, 
stool analysis.[5-8] After detection of CRC and/or CRLM, the primary tumor will be surgically 
resected – if technically possible. After resection of the primary tumor, patients are offered an 
intense 5-year follow-up program consisting of multiple scans and CEA measurements. The 
5-year survival rate is 40-50% [9, 10], and the 5-year disease-free survival rate is 20-30% [10].
A possible alternative to the above-mentioned techniques is a targeted mass spectrometry 
method analyzing natural occurring peptides (NOPs) of collagen in urine, described by 
Broker et al. and Lalmahomed et al.[11, 12] Urine was selected as a biofluid since large volumes 
can easily be collected non-invasively. Furthermore, it is much more convenient for a patient 
to hand-in urine, then to visit a hospital for a CT-scan. Analysis of a combination of collagen 
NOPs in urine and serum CEA resulted in a sensitivity of 85% and a specificity of 84% for the 
detection of colorectal liver metastases[12], which figures are comparable to those obtained 
with the currently used techniques [5, 13, 14], although not yet sufficient for clinical use. In this 
thesis we describe possibilities to find markers for metastasis of primary colorectal cancer.
The interest in this thesis is focused on the family of collagen proteins as potential markers for 
CRLM. Members of the collagen family have the ability to form a triple helix, and contain many 
posttranslational modifications. With the availability of state-of-the-art mass spectrometry 
collagen can be studied in relation to CRLM. An in-depth introduction to collagen and the 
analysis of collagen with mass spectrometry is provided in Chapter 2. The aim of this thesis 
is to improve the combination method of analyzing collagen NOPs in urine and serum CEA 
to detect CRLM by expansion of the collagen NOP panel. The discovery and validation of 
additional collagen NOPs in urine to improve the detection of CRLM is described in Chapter 
3. It is difficult to prove that the collagen NOPs measured in urine directly originate from the 
CRLM. Therefore, we further investigated collagen in colon, CRC, liver, and CRLM tissues to 
gain better insight in collagen pathology. In Chapter 4, the upregulation, at the protein level, 
of collagen in CRLM and the similarity in expression levels to colon, CRC, and liver tissue has 
been described. Chapter 5 describes the collagen hydroxylation pattern between colon, CRC, 
liver, and CRLM tissue. Chapter 6 places a focus on the identification of an unknown proline 
hydroxylation. In the general discussion in Chapter 7, the results of the studies described in 
this thesis are discussed and summarized.
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CHAPTER 2
Collagen analysis 
with mass spectrometry
ABSTRACT
Mass spectrometry-based techniques can be applied to investigate collagen with respect to 
identification, quantification, supramolecular organization, and various post-translational 
modifications. The continuous interest in collagen research has led to a shift from techniques 
to analyze the physical characteristics of collagen to methods to study collagen abundance 
and modifications. In this review we illustrate the potential of mass spectrometry for in-
depth analyses of collagen.
Reprinted with permission from Mass Spectrometry reviews. Copyright 2019 John Wiley and 
Sons.
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I. INTRODUCTION
Proteins that belong to the collagen family are the most abundant proteins in the animal 
kingdom [15]. Approximately 30% of the protein content of the human body consists of 
collagen [15], and structures like bone (the organic part) and tendon might even consist of 
more than 90% of collagen [16]. Collagen has not been identified in only a few tissues, such as 
nail plates, hair shafts, and the eye lens [17-20]. 
So far, twenty-eight different collagen types have been identified – each with its specific 
characteristics. A collagen type consists of one to six of 45 different alpha chains, see below. 
In each collagen type, three alpha chains twisted around each other form a triple helix. 
On the basis of their supramolecular structure, eight subgroups of collagen types can be 
distinguished [21, 22]. Multiple triple helices form collagen supramolecular structures via 
covalent and non-covalent bonding, and these supramolecular structures can consist of 
multiple collagen types.
Collagen is a major component of the extracellular matrix (ECM). Frantz et al. have defined 
the ECM as: “The non-cellular component present within all tissues and organs, and provides 
not only essential physical scaffolding for the cellular constituents but also initiates 
crucial biochemical and biomechanical cues that are required for tissue morphogenesis 
differentiation and homeostasis” [23]. Among other functions, collagen is involved in handling 
physical stress and supporting tissue structures. Dysregulation of specific collagen types can 
have devastating effects. Mutations in collagen-related genes may cause various diseases, 
such as Alport syndrome, Bethlem syndrome, Ehlers-Danlos syndrome, and osteogenesis 
imperfecta (OI). A change in collagen turnover caused by external influences (e.g., scurvy or 
fibrosis) also results in a diseased state. Collagen also plays a role in tumor development and 
metastasis [24-26]. For the reader interested in the role of collagen in fibrosis we recommend the 
review of Karsdal et al. [27].
Although much is already known about collagen, a literature search will reveal a substantial 
lack of knowledge about, among other things, posttranslational modifications and collagen 
function. Mass spectrometry has great potential to contribute to our knowledge on collagen. 
To identify areas that lack knowledge, we searched for articles that match the search criteria 
“collagen” and “mass spectrometry” at “Web of Science”, and have been cited over 30 times 
from 2010 up to 2019. In addition, we included older or newer articles or articles with fewer 
citations that contain valuable information about collagen. As a result, 41% of the references 
in this review date from 2010-2019, and 79% date from 2000-2019.
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In section 1, we discuss collagen nomenclature and the production of collagen from DNA 
to the formation of supramolecular collagen structures. Section 2 describes the structural 
and functional characteristics of collagen as a background to this review, although most of 
the research referred to in this section was performed without mass spectrometry. Several 
gaps in collagen knowledge are pointed out and addressed. Mass spectrometry has the 
potential to fill up these gaps. Section III describes use of mass spectrometry in the analysis of 
collagen, and introduces circular dichroism and (immunohistochemistry) staining applied 
in collagen research.
I-A. COLLAGEN NOMENCLATURE
An overview of the nomenclature of the collagen triple helix is shown in figure 1. A collagen 
triple helix consists of three alpha chains, which after folding form procollagen. A collagen 
molecule, containing the triple helix, is formed by enzymatic cleavage of the terminal N- and 
terminal C-propeptides. If during the translation of an alpha chain the addition of post-
translational modifications (PTMs) is interrupted, then the collagen molecule formed would 
be called a protocollagen. PTMs are modifications of the protein that are not encoded in the 
DNA and can alter the protein function. In literature, the plural “collagens” might be used; 
however we recommend using “collagen” because it is a collective noun.
In addition, different nomenclature styles for collagen types and alpha chains exist. The 
specific collagen type is annotated, for instance, as type 3, or (III), or III. The numbering follows 
the order of discovery [21, 22]. The specific alpha chain is represented by addition of an alpha 
numbering; for instance, alpha-1(III), or α1(III). Only the abbreviations for the collagen genes 
are used consistently in literature, and are also often used as the protein name abbreviation. 
The gene abbreviation is, for example, COL3A1, which stands for the protein collagen alpha-
1(III). The stoichiometry of a collagen triple helix is annotated as [α1(I)]2 α2(I) – a collagen 
type I that consists of two alpha-1 chains and one alpha-2 chain.
Figure 1. Nomenclature of the primary and secondary structures of the collagen triple helix.[28] Reprinted 
with permission from the author.
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I-B. FROM DNA TO SUPRAMOLECULAR STRUCTURES 
A schematic overview of collagen and fiber formation is shown in figure 2. The actual picture 
can be slightly different for the various collagen types and the supramolecular structures 
formed. Like any other protein, the primary amino acid structure of collagen is defined by 
DNA. Collagen genes are transcribed from DNA into RNA in the cell core and translated into 
a protein on ribosomes mostly present in the endoplasmic reticulum [29]. The protein formed 
is the building block of collagen and is called an alpha chain. Alpha-chain formation and 
the production of a complete procollagen molecule takes place in approximately 6 min 
(translational speed of ≈209 residues per min) [30].
Collagen contains various PTMs, such as hydroxylation of proline and lysine, oxidation 
of lysine, glycosylation of hydroxylated lysine, and cross-linking of oxidized lysine. 
Hydroxylation of proline and lysine, and glycosylation already start during the translation of 
the alpha chain and finish shortly after translation.
After translation and the addition of PTMs, three alpha chains of the same collagen type are 
linked together by sulfur bridges formed between specific cysteine’s. Correct alignment of 
alpha chains is crucial for correct folding of a triple helix. The triple helix-forming regions in 
collagen contain the repetition of three amino acids (Gly-Xaa-Yaa; also written as Xaa-Yaa-Gly) 
in the primary amino acid sequence. The following pattern: Gly-Xaa-Yaa-[Gly-Xaa-Yaa]n-Gly-
Xaa-Yaa is present in the triple helical forming regions. In this pattern, glycine (Gly) points to 
the inside of the triple-helix. The triple helix is formed by a zipper-like folding mechanism. 
The rate-limiting step of triple helix folding is the requirement of all proline moieties to be 
in a trans conformation. In most amino acids, the trans conformation is energetically the 
more stable confirmation; however, proline contains a ring that allows the cis- and trans-
conformation [31]. Proline is actively transformed from the cis- to the trans- conformation by 
peptidyl-prolyl cis-trans isomerase (PPIase) [32]. Triple-helical folding is sensitive to mutations 
of the primary alpha chain that inhibit further folding. Amino acid substitution of especially 
glycine inhibits helix formation due to steric hindrance. The rate-limiting step of collagen 
folding is the transformation of cis-proline into trans-proline [32]. 
The protein formed after triple helix-folding is called procollagen. The triple-helical region 
of procollagen is twisted in a right-handed way (clockwise); the alpha chains themselves are 
twisted in a left-handed way (counterclockwise). 
All processes described so far take place inside a cell; at this stage, however, collagen is 
excreted into the ECM via the Golgi apparatus [33, 34]. During this event, triple-helix unwinding 
is prevented by so-called chaperone proteins (e.g., heat shock protein 47), which stabilize the 
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triple helix [35]. Furthermore, C- and N-propeptides are both cleaved off by enzymatic activity. 
The removal of the C- and N-propeptides stimulates the self-assembly of supramolecular 
structures [36]. The collagen supramolecular structures [29] are further stabilized by formation 
of covalent cross-linking and non-covalent bindings. Covalent cross-linking of collagen is 
mainly initiated by oxidation of lysine by lysyl oxidase. The oxidation of lysine occurs in the 
ECM [21, 37].
The produced collagen triple helix is built into large fibers. The type of fiber formed depends 
on the collagen types involved [21]. However, collagen types of similar composition can form 
different fiber types. For example, in the skin, collagen is mainly located in the dermis. The 
papillary layer contains collagen fibers of 0.3-3.0 µm thick, which are made of much thinner 
fibers with a diameter of 20-40 nm. These fibers form a loose network with no particular 
orientation [38]. The reticular layer is located below the papillary layer, which contains fibers 
with diameters between 10 and 40 µm made of collagen type I. These fibers form more 
compact and better arranged structures [38]. [38] obtained several images made by scanning 
electron microscopy that illustrate the above described networks in the skin and also show 
how a blood vessel is connected to the surrounding network by collagen fibers. Tateya et al. 
identified collagen type I in the vocal folds with immuno-scanning electron microscopy [39]. 
This technique enables to distinguish collagen type I and type III. Thus, Kadler et al. visualized 
collagen fibers in tissue, and produced a movie of consecutive tissue sections showing how 
the collagen fiber ’moves’ through tissue [40].
Not only the fiber thickness varies, but also the ratio between, for example, collagen type 
I and II in skin. The latter ratio decreases during aging [41]. Besides the heterotypic fiber in 
the skin consisting of collagen type I and III, other heterotypical fibers exist. The 10+4 fiber 
is a supramolecular organization whereby four microfibrils are surrounded by a ring of ten 
microfibrils. The four core fibrils consist of two collagen type II and two collagen type XI 
microfibrils. Individual collagen type IX helices are assumed to be present at the surface of 
collagen type XI at the N-terminus, preventing further addition of microfibrils and thereby 
regulating fiber thickness [42]. An exception is the so-called super-twisted microfiber, which is 
formed of five collagen type I triple helices twisted around each other. These super-twisted 
microfibers interact with each other, thereby forming a hexagonal fiber purely made of 
collagen type I [43]. Fibers in cartilage are made of collagen types I and III, or collagen types II, 
IX, and XI, or collagen types II and III [44].
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Figure 2. Schematic overview of collagen type I fiber formation from translation to fibers.[21] Reprinted 
with permission from the authors, 2004 Elsevier.
II. STRUCTURAL AND FUNCTIONAL CHARACTERISTICS 
OF COLLAGEN
II-A. PRIMARY STRUCTURE
II-A-1. Amino acid sequence
The most important property of collagen is its ability to form a triple helix. The ability to form 
a quaternary structure can be readily observed from the repetitive primary structure specific 
for a specific domain in the amino acid sequence, the helical domain. This domain consists of 
a tripeptide polymer with a distinct pattern, [Gly-Xaa-Yaa]n. The amino acid glycine, which has 
the smallest side chain (-H), is located at the inside of the triple helix. A mutation of glycine 
into any other amino acid will result in steric hindrance – and consequently an imperfectly 
folded triple helix – or even inhibition of triple helix formation. [45-47] 
In theory, four hundred different tripeptides patterns (Gly-Xaa-Yaa) can be expected just by 
chance (Xaa and Yaa are variable amino acids that yield a random variation of 20 times 20). 
In reality, not all amino acids are present at the Xaa or Yaa position, probably due to steric 
hindrance and helix stability. Ramshaw et al. have provided an overview of the appearance 
frequency given by for a limited number (n=14) of alpha chains from 12 collagen types [48]. The 
10 most frequent tripeptides make up 39% of the helical domain, of which 10.5 % is GPP. Proline 
itself is in 55.7 % of cases located at the position Xaa, Yaa, or both. Other amino acids such as 
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cysteine, phenylalanine, glycine, histidine, tryptophan, and tyrosine are hardly present at the 
Xaa or Yaa position. Also, some amino acids are more often found at the Xaa than at the Yaa 
position or vice versa, such as lysine and leucine [49]. These amino acids might be present due 
to effects on the melting temperature (Tm); the Tm will be discussed in more detail in II-A-2.
The helical domain is not the only functional group present in the primary structure. At 
the N- and C-terminus of the triple helix, telopeptides and propeptides are located. At the 
N-terminus, a propeptide is located that serves as a signal peptide. Signal peptides “tell’’ the 
cell the destination of a protein. Furthermore, propeptides and telopeptides are involved in 
collagen cross-linking and the alignment of three alpha chains for triple helix formation.
Furthermore, in the primary structure of the non-helical regions of collagen, information can 
be present for angiogenesis inhibition. Three of the six collagen type IV alpha chains, collagen 
type XV, and collagen type XVIII contain angiogenesis inhibitor information (see table 1). 
Table 1. Angiogenesis inhibitors present in the primary structure of the non-helical domains of collagen.
Collagen type Angiogenesis inhibitor
COL4A1 Arresten [50, 51]
COL4A2 Canstatin [51-53]
COL4A3 Tumstatin [54]
COL15A1 Restin (Endostatin-like) [51, 55]
COL18A1 Endostatin [56]
Mass spectrometry has played an important role in the analysis of collagen angiogenesis 
inhibitors. Angiogenesis in healthy tissue occurs only in tissue repair, physical exercise, and 
in the female reproduction cycle [51, 57]. However, angiogenesis is activated by several diseases, 
such as psoriasis, rheumatoid arthritis, diabetic retinopathy, and cancer [51]. Endostatin, 
which functions as an anti-angiogenic cytokine, was first detected in human blood with the 
use of mass spectrometry (MALDI-MS and ESI-MS) and N-terminal sequencing [58]. Standker et 
al. showed the presence of sulfur bridges between cysteine residues 1-3 and 2-4. Later analysis 
with mass spectrometry (MALDI-TOF and ESI-Ion trap) showed that cysteine residues 1-4 
and 2-3 were connected in endogenous endostatin [59]. Furthermore, John et al. showed that 
recombinant endostatin, used as drug, also has sulfur bridges between cysteine residues 
1-4 and 2-3, which are similar to those in endogenous endostatin. A few years later, the same 
group identified new proteolytic forms of endostatin and restin, with two different forms of 
O-glycosylation, with the use of chromatographic purification, followed by characterization 
and sequencing with mass spectrometry and Edman degradation [60]. 
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II-A-2. Triple-helix stability and melting temperature
The amino acid sequence of collagen alpha chains contains specific motifs that allow the 
formation of a triple helix and the assembly of other supramolecular structures such as fibers 
and basement membranes. A single mutation in the primary amino acid sequence can prevent 
triple-helix formation and can, for that reason, result in a diseased state (e.g., osteogenesis 
imperfecta), which can be lethal [46]. Local variations in stability gives rise to micro-unfolding 
that can lead to, for example, enzyme activity, cell attachment, and remodeling of connective 
tissue.
The thermal stability of the collagen triple helix is defined by its Tm. In general, if the 
temperature equals a protein’s Tm, half of these proteins are folded, and half are unfolded; 
if the temperature exceeds the Tm, then these proteins unfold. The Tm of a triple helix is 
assumed to be a few degrees above body temperature [61]. The Tm of collagen type I, however, 
is a few degrees below body temperature, and this probably holds for other collagen types 
as well [61]. At a too low Tm, the triple helix formed would unfold before a supramolecular 
structure could be formed. The denaturation time is similar to the time required to build a 
triple helix into a supramolecular structure. In addition, Leikina et al. state: “Our data support 
an earlier hypothesis that in fibers collagen helices may melt and refold locally when needed, 
giving fibers their strength and elasticity”. 
When a fiber is formed from multiple triple helices, the Tm increases strongly by 
approximately 27 °C, to 72 °C [62]. The large increase in Tm is probably the result of additional 
stabilization due to increased interactions between the various triple helices and the lack of 
water in the formed fiber, making the fiber more compact.
Apart from the primary amino acid sequence, PTMs also help increase the triple-helix 
stability as a result of additional cross-links and extra hydrogen bridges [63]. The amount of 
PTMs increases by culturing fibroblasts at an elevated temperature, probably due to a slower 
folding rate, which will result in a longer reaction time for the enzymes responsible for PTM 
formation to modify amino acids [64]. The Tm of the triple helix will probably not exceed the 
elevated temperature unless more PTMs are added. 
II-B. POST-TRANSLATIONAL MODIFICATIONS
II-B-1. Overview of post-translational modifications and enzymes involved
Besides the characteristic tripeptides in collagen, other characteristics of great importance 
for triple-helix stability and cross-linking can be found in the primary structure, namely 
PTMs. The most common PTMs can be divided into three groups: hydroxylation/oxidation, 
glycosylation, and cross-linking. 
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The two amino acids most often involved in collagen PTMs are proline and lysine. The 
most important PTMs are shown in figure 3. The most important enzymes involved in PTM 
formation are given in table 2. Molecular oxygen is important in the hydroxylation/oxidation 
of proline and lysine. A lack of oxygen reduces the amount of hydroxylated proline and lysine; 
hydroxylation of proline becomes the rate-limiting step of triple-helix formation, leading to 
fewer cross-links, reduction of fiber organization and density, and loss of tensile strength [65-68].
Figure 3. PTMs of proline and lysine.
Table 2. Most important enzymes involved in collagen PTM formation.
PTM Enzymes involved Uniprot code
4-hydroxyproline P4HB
P4HA1
P4HA2
P4HA3
P07237
P13674
O15460
Q7Z4N8
3-hydroxyproline P3H1 
P3H2
P3H3 
CTRAP
CYPB
Q32P28
Q8IVL5
Q8IVL6
O75718
P23284
5-hydroxylysine PLOD1
PLOD2
PLOD3
Q02809
O00469
O60568
Allysine LOX
LOXL1
LOXL2
LOXL3
LOXL4
P28300
Q08397
Q9Y4K0 
P58215
Q96JB6
5-hydroxyallysine Combination of 5-hydroxylysine and allysine enzymes
O-glycosylation PLOD3
COLGALT1
COLGALT2
O60568
Q8NBJ5
Q8IYK4
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Mass spectrometry can be used to analyze collagen PTMs. Collagen PTMs have been mapped 
with mass spectrometry for a number of collagen types (COL5A1 Bos Taurus, COL2A1 Bos Taurus, 
COL4A1 Mus musculus, and COL4A1 human) [69-73]. Mapping all PTMs requires, among other 
things, different enzymes and complementary fragmentation techniques. Uncertainties will 
remain, even then. This approach has also resulted in the interesting finding of a hydroxylated 
proline at the Xaa position.[69-73]. Its hydroxylation form is ambiguous, because hydroxyproline 
at the Xaa position does not match known enzyme activity; see II-B-2 and II-B-3. With the use of 
mass spectrometry it proved possible to establish that the PTM was either 3-hydroxyproline or 
4-hydroxyproline, as shown by Kassel et al. in mussel adhesive proteins [74]. However, van Huizen 
et al. recently obtained, with mass spectrometry, the proof of principle that hydroxyproline 
at the Xaa position (amino acid position 584) in COL1A2 is 4-hydroxyproline [75]. The authors 
suggested naming this new PTM ‘4xHyp’. The ’x’ differentiates between the Xaa and Yaa position. 
The identification of 4xHyp was achieved by applying ETD-HCD (MS/MS/MS) fragmentation 
on GLHGEFGLP(4Hyp)GP(?xHyp, pos. 584)AGPR, which contains the 4xHyp PTM of interest. 
Synthetic peptides containing 3Hyp, 4Hyp, Pro at the position of the 4xHyp were measured. The 
peptide containing 3Hyp and the peptide containing 4Hyp had different retention times and 
fragmented differently, whereby m/z 400 and 454 were distinctive between 3Hyp and 4Hyp, see 
the mass spectra in figure 4. The exact function of 4xHyp is unknown. 
 
Figure 4. Zoom-in of the ETD-HCD mass spectra of the synthetic peptides acquired by direct infusion. 
GLH-3Hyp and GLH-4Hyp are distinguishable by singly charged fragments at m/z 400 and 454.[75]. 
Reprinted with permission from the authors, 2019 ACS Publications.
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II-B-2. (2S,4R)-4-Hydroxyproline
Below, the normal 4-hydroxyproline is discussed, not the newly identified 4xHyp.
(2S,4R)-4-Hydroxyproline (in the following section referred to as 4-hydroxyproline or 4Hyp 
as three-letter amino acid code) is the most common PTM in collagen. Its function is well 
known: building hydrogen bridges -via one to three water molecules- with other amino acids 
from one of the other three alpha chains, therefore increasing stability.
Proline is hydroxylated into 4Hyp via enzymatic activity of prolyl 4-hydroxylase (P4H). 
Prolyl 4-hydroxylase consists of two alpha-subunits and two beta-subunits (protein disulfide 
isomerase) [76, 77]. Three alpha subunits are known for prolyl 4-hydroxylase: P4HA1, P4HA2, and 
P4HA3. The chemical reaction is shown in figure 5.
 
Figure 5. Chemical reaction of the hydroxylation of proline by proline 4-hydroxylase.
The Gly-Xaa-Pro substrate is required for hydroxylation of proline with P4H [78]. Amino acids 
at the Xaa position strongly influence the degree of proline hydroxylation [79]. 
A minimum number of hydroxylations is required to obtain a Tm that is sufficient to prevent 
unfolding before the triple helix can be built into supramolecular structures. Utting et al. 
found with amino acid analysis that, if hydroxylation of proline became the rate-limiting step 
of collagen formation, then the amount of hydroxyproline decreased from 43.9% to 42.2% [68]. 
A study by Rapaka et al. indicates a certain randomness in the hydroxyproline pattern [79]. The 
hydroxylation pattern should be further assessed to identify possible prevalent hydroxylation 
positions. To this aim, it would be interesting to compare the collagen hydroxylation pattern 
on the individual level. Mass spectrometry would be the ideal technique to this aim. The 
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randomness of hydroxyproline can be determined in tissues and cell cultures with standard 
bottom-up proteomics and with proteomics databases (PRIDE archive). Montgomery et 
al. showed with mass spectrometry the frequency of occurrence of proline hydroxylation 
in COL1A1 [73]. However, information regarding the variation between organs, diseases, and 
organisms is still lacking.
Three alpha chains self-associate at a specific point by sulfur bridges between several cysteine’s; 
from that point onwards the triple helical folds in the way a zipper is closed [80, 81]. The rate-
determining step of collagen folding is cis/trans isomerization of proline by peptidyl-prolyl 
cis-trans isomerase (PPIase), whereby trans proline is required for folding. During enzymatic 
hydroxylation of proline into 4Hyp by P4H, only 4R-hydroxyproline is formed. The possible 
influence of 4S-hydroxyproline on the cis/trans isomerization was tested by Bretscher et al. 
[82]; it was found that a hydroxyl group present in the S-position reduced the cis/trans ratio 
and lowered the Tm dramatically. 
Furthermore, an error in enzyme P4H, or aberrant levels of the necessary cofactors, can 
influence the enzyme’s function. Non-optimally functioning of the enzyme likely results 
in under-hydroxylated collagen. As described in II-A-2, under-hydroxylated collagen is less 
likely to be built into supramolecular structures. Giunta et al. showed with HPLC that under-
hydroxylated collagen is present in the urine of patients with a specific form of Ehlers-Danlos 
syndrome [83]. Zn2+ is present in the cell at a higher level, and possibly interferes with the 
cofactor Fe2+, thereby inhibiting proline hydroxylation.
Levels of 4Hyp in a sample can be determined with LC-MS and GC-MS. For LC-MS analysis, 
hydrolysis with hydrochloric acid is required [84-87]; GC-MS analysis requires an additional 
derivatization step to measure 4Hyp [88]. For LC-MS analysis, glycylphenylalanine [86] and 
N-methyl-L-proline [84, 85, 87] may serve as internal standards. For mass spectrometry 
analysis, however, it is recommended to use a stable isotope-labelled version of the analyte 
of interest [89, 90]. The analysis of 4Hyp will give information on the change in collagen levels. 
The original articles regarding the LC separation of hydroxyproline mention the separation 
of cis- and trans-4-hydroxyproline, and the separation of 3-hydroxyproline and 4Hyp [91, 92]. 
However, in later publications the separation of hydroxyproline isomers is not discussed. 
Probably, 3-hydroxyproline and 4-hydroxyproline levels were obtained simultaneously, 
which gives biased results.
II-B-3. (2S,3S)-3-Hydroxyproline
Apart from 4Hyp, (2S,3S)-3-hydroxyproline also exists as a proline PTM (3-hydroxyproline 
or 3Hyp as three-letter amino acid code). The mass of 3Hyp (113.05 Da) is equal to that of 
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its isomer 4Hyp and similar to those of its isobars leucine/isoleucine (113.08). The mass of 
the tripeptide Gly-Ala-Hyp is identical to that of its isomer Gly-Ser-Pro. The differentiation 
between Gly-Ala-Hyp and Gly-Ser-Pro can, with mass spectrometry, be based on b- and y-ions. 
Kassel et al. demonstrated that 3Hyp, 4Hyp, leucine, and isoleucine have different w- and 
a-ions, by which they can be distinguished [74]. W- and a-ions are formed upon fragmentation 
of amino acids side chains.
3Hyp is formed by an enzymatic reaction of prolyl 3-hydroxylase with proline. Until now, three 
different subunits are known for prolyl 3-hydroxylases (P3H): P3H1, P3H2 and P3H3.[93]. P3H1 
forms a complex with cartilage-associated protein (CTRAP) and prolyl cis-trans isomerase 
cyclophilin B (CYPB) [94]. The reaction scheme of prolyl 3-hydroxylase is similar to that of 
prolyl 4-hydroxylase [95]. The discovery that mutations of CTRAP could cause a recessive form 
of osteogenesis imperfecta has increased the interest in 3Hyp [94, 96].
3Hyp is not present in all collagen types; it is present only in collagen types I, II, III, IV, V, and 
XI [97]. The amount of 3Hyp per collagen alpha chain is much lower than the amount of 4Hyp; 
the hydroxylation of proline into 4Hyp is sometimes even assumed to be 100% [98]. While 3Hyp 
occurs only at 1 or 2 positions in collagen types I and II, it occurs at 3-6 positions in collagen 
types V and XI. COL1A1 contains 47x Gly-Pro-Pro, which indicates that many possible substrates 
exist for P3H. However, in collagen type IV, which is part of the basement membrane, 10% of 
the total number of hydroxyprolines can be a substrate for 3Hyp. Furthermore, with mass 
spectrometric analysis it was shown that the 3Hyp frequency is tissue type-dependent [99]. 
Mass spectrometry analysis of periodontal ligament in human and mouse showed an absence 
of 3Hyp in collagen type I [100]. 
Eyre et al. and Weis et al. identified 3Hyp with mass spectrometry in several collagen types; 
subsequent analysis of the surrounding amino acid sequences was performed for sequence 
commonalities [99, 101]. An overview of the identified 3Hyp substrates is shown in table 3.
Table 3. In literature mentioned 3Hyp positions [99, 101]
Collagen type Position1 Site2 Sequence3
V α-1 434 B3 GET-GFQ-GKT-GPP-GPP-GVV
XI α-1 434 B3 GET-GFQ-GKT-GPP-GPG-GVV
XI α-2 434 B3 GEV-GFQ-GKT-GPP-GPP-GVV
V α-2 470 A4 GFQ-GLP-GPP-GPP-GEG
V α-1 665 B2 GDE-GPR-GFP-GPP-GPV-GLQ
XI α-1 665 B2 GDE-GAR-GFP-GPP-GPI-GLQ
XI α-2 665 B2 GDE-GTR-GFN-GPP-GIV-GLQ
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Table 3 continued.
Collagen type Position1 Site2 Sequence3
V α-1 692 B1 GDV-GQM-GPP-GPP-GPR-GPS
XI α-1 692 B1 GDV-GPM-GPP-GPP-GPR-GPQ
XI α-2 692 B1 GDV-GPM-GPP-GPP-GPR-GPA
I α-2 707 A3 GFP-GAA-GRT-GPP-GPS
V α-2 707 A3 GFP-GSA-GRV-GPP-GPA
II α-1 944 A2 GFT-GLQ-GLP-GPP-GPA
V α-2 944 A2 GFT-GLQ-GLP-GPP-GPN
I α-1 986 A1 GLN-GLP-GPI-GPP-GPR
II α-1 986 A1 GAN-GIP-GPI-GPP-GPR
V α-2 986 A1 GNP-GPL-GPI-GPP-GVR
1Position (positional counting) includes signal peptides and other parts which are nominally present.
2 Modification that occurs at a certain site in the alpha-chain.
3P is 3Hyp, P reported as 4Hyp.
From table 3, we can conclude that the common substrate for site A1 is G?N-G”I/L”?-GPI-GPP-
GPR; this motif is not present in the other sites. The “?” in the motif represents the possibility 
of implementation of different amino acids. In the first tripeptide part (GLN, GAN, or GNP), 
the position of asparagine is variable. In the second tripeptide part, the positons of proline 
and (iso)leucine are variable. This variability is probably not of much influence. For sites A2, 
A3, A4, and B2, the only shared motif is a phenylalanine (F), nine positions or less to the left 
of 3Hyp (P). In B1, phenylalanine is not present. It should be noted that the distance between 
sites A2 and A3 and that between A3 and A4 is 237 amino acids, and that the distance between 
B2 and B3 is 231 amino acids. These distances are remarkably close to the D-spacing (230-240 AA 
(≈60 nm)), which varies per tissue type [102]. The D-spacing or D-period is the distance between 
the N- and C- terminus of two triple helices in a fiber [103, 104]. This distance indicates that 3Hyp 
might play a role in fiber formation and other supramolecular structures in collagen. P3H1 is 
assumed to be responsible for 3Hyp at position 986. Sites A2, A4, B1, and B2 are assumed to be 
formed by P3H2. More research is necessary to more fully understand the mechanism for the 
formation of 3Hyp and its influence on the functionality in collagen. Indeed, the influence of 
3Hyp on the collagen Tm is of interest to understand the possible function of 3Hyp. Jenkins et 
al. analyzed the influence of 3Hyp on the Tm of a guest peptide [105]. Substitution of a 3Hyp at 
the Yaa position resulted in a decreased Tm (-10oC), whereas substitution of a 4Hyp increased 
the Tm (+4oC). Surprisingly, after substitution of more than one 3Hyp, the Tm started to 
increase again [106].
 
II-B-4. Lysine
Lysine, too, can have PTMs. Lysine can be modified into two different derivatives: 1) allysine, 
whereby the ε amine of lysine is transformed into an aldehyde; and 2) 5-hydroxylysine, 
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whereby the 5th carbon is hydroxylated, comparable to hydroxyproline. The amine group 
of hydroxylysine can be further oxidized into an aldehyde (hydroxyallysine). While 
5-hydroxylysine is formed inside the cell, allysine and hydroxyallysine are formed in the ECM. 
The chemical structures of the lysine PTMs are given in figure 3.
All lysine modifications are a result of enzymatic activity and can be intermediate steps for 
further modifications, such as cross-linking and glycosylation. The abundance of allysine 
and that of hydroxylysine in the C- and N-non-helical domains are tissue-dependent: 
allysine is dominant in soft connective tissue (e.g., skin); hydroxyallysine is dominant in 
skeletal connective tissue (e.g., bone, tendon) [107, 108]. In this review, only the formation of 
5-hydroxylysine, allysine, and hydroxyallysine and their functions are discussed; other PTMs 
based on these lysine modifications are discussed later (glycosylation, cross-linking).
II-B-4a. 5-Hydroxylysine
An intermediate step of glycosylation of collagen, 5-Hydroxylysine, is formed by an enzymatic 
reaction of lysyl hydroxylase (LH) with lysine; the hydroxylation pathway is comparable 
to prolyl 4-hydroxylase. Lysyl hydroxylase also goes by the name of procollagen-lysine, 
2-oxogluterate 5-dioxygenase (PLOD). The required substrate is Xaa-Lys-Gly in the helical 
domain and Xaa-Lys-Ala or Xaa-Lys-Ser in the telopeptides (both C and N termini) [109]. So far, 
three slightly different isoforms of lysyl hydroxylase have been identified in humans [110].
Lysine in the helical region is hydroxylated by lysyl hydroxylase 1. It has been suggested that 
lysyl hydroxylase 2 (LH2) modifies lysine in the telopeptides [111]. Lysyl hydroxylase 3 (LH3) is 
assumed to hydroxylate lysine, galactosylation, and glycosylation of 5-hydroxylysine [111].
II-B-4b. Allysine
Lysine can also be modified into allysine by lysyl oxidase (protein-lysine 6-oxidase, LOX), in 
which reaction the amine group is transformed to an aldehyde group. The reactive aldehyde 
group is important for collagen cross-linking. In total, five lysyl oxidase enzymes are known 
– four belong to the family of lysyl oxidase like proteins (LOXL). Lysyl oxidase is strongly 
bound to copper(II) [112]. As opposed to lysyl hydroxylation and prolyl hydroxylation, which 
are intracellular processes, lysyl oxidation is an extracellular process [113]. The latter’s reaction 
scheme is different too: lysine + O2 + H2O → (LOX) → allysine + NH3 + H2O2 [114].
LOXL-2 is involved in collagen type IV lysyl oxidation, whereas other LOX and LOXL enzymes 
are involved in lysyl oxidation of fibril-forming collagen types. The enzymatic activity of 
LOX is not limited to collagen – elastin is also oxidized by LOX [115]. The substrate specificity 
of LOX has been studied in a similar manner to P4H. The kinetics of LOX was determined 
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with fluorescence measurements of the formed H2O2 
[116]. In general, LOX oxidizes lysine in the 
presence of a variety of other adjacent amino acids; the reaction rate is influenced by these 
other amino acids. For example, the hydroxylation rate decreases with increasing size of the 
side chain (Ala>Val>Leu>Phe); and a negative charge located next to lysine (e.g., glutamic 
acid) also negatively affects the hydroxylation rate. On the other hand, a positive charge (e.g., 
lysine or arginine) located next to lysine exerts a positive effect on the hydroxylation rate [116].
II-B-4c. Hydroxyallysine
Hydroxyallysine is formed by a combined enzymatic activity of lysyl hydroxylase and lysyl 
oxidase. The formation of 3-hydroxyallysine occurs by hydroxylation of lysine, followed by 
oxidation of the amine into an aldehyde. Due to the highly reactive character of the aldehyde, 
3-hydroxyallysine will rapidly form cross-links (see also section II-B-7).
II-B-5. Collagen glycosylation
Protein glycosylation is known for its complexity. During glycosylation, sugar branches 
(glycans) are added to proteins. Glycans can be attached to oxygen or nitrogen of the functional 
sidechain of an amino acid. Both O- and N-glycosylation are present in collagen [117, 118]. We refer 
to a review by Perdivara et al. in which the current status of collagen O-glycosylation analysis 
with mass spectrometry is discussed [118]. Furthermore, the O-glycosylation of collagen type IV 
has been mapped with mass spectrometry by Basak et al. [71].
In comparison to O-glycosylation, hardly anything is known about N-glycosylation of 
collagen.[119, 120] With mass spectrometry, the glycans attached by N-glycosylation to collagen 
can be identified [121, 122].
II-B-5-a. O-linked collagen glycosylation
The two forms of O-linked glycosylation that occur in collagen are a galactose connected 
to 5-hydroxylysine (galactosyl-hydroxylysine, G-Hyl), or a galactose-glucose connected to 
5-hydroxylysine (glucosylgalactosyl-hydroxylysine, GG-Hyl). Glycosylation of 5-hydroxylysine 
in collagen is achieved by hydroxylysyl galactosyltransferases, galactosylhydroxylysyl 
glucosyltransferases, and lysyl hydroxylase 3. The chemical structure of GG-Hyl is shown in 
figure 6. Schegg et al. showed the possibility to identify new galactosyltransferases with a 
combination of affinity chromatography and mass spectrometry [123]. The function of O-linked 
glycosylation is largely unknown, but it has been suggested that collagen glycosylation is 
involved in collagen fibrillogenesis and cross-linking.
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Figure 6. 2-O-α-D-glucopyranosyl-O-β-D-galactopyranosylhydroxylysine (GG-Lys).
II-B-5b. Fibrillogenesis
Experiments have shown that GG-Hyl influences collagen-fiber formation. The diameter of 
a glycosylated collagen fiber decreases with increasing glycosylation. The high hydrophilic 
character of the glycosylation could induce formation of a water layer around the glycans. 
The glucose-galactose unit is assumed to be oriented parallel to the triple helix to shield 
three to four amino acids from interactions with other triple helices. These phenomena are 
expected to influence collagen-fiber formation [64, 124].
II-B-5c. Cross-linking
Initial analysis of collagen cross-links in combination with glycosylation has resulted in two 
hypotheses. 1) Immature cross-links are often connected to GG-Hyl, whereas 2) mature cross-
links are more often connected to G-Hyl or non-glycosylated allysine. Cross-linking will be 
discussed in more detail in II-B-7. Mass spectrometry demonstrated that the relation between 
mature cross-links and glycosylation was a tissue-specific one [125, 126]. The relation between 
collagen glycosylation and cross-linking has not been proven irrefutably, and current 
experiments point to a more tissue-specific correlation [126].
II-B-6. Advanced glycation end-products (AGE)
Apart from enzymatic glycosylation, also non-enzymatic glycosylation occurs (glycation), 
whereby carbohydrates react with proteins, lipids, or nucleic acids [127]. Cross-linking occurs 
by further reaction of glycation moieties (advanced glycation end products (AGE)). Together 
with certain types of cross-linking, AGE is a factor involved in collagen maturation. In general, 
AGE only affects proteins with turnover longer than a few weeks.
AGE formation starts by the reaction of saccharides (fructose, glucose etc.) with the amine 
groups of proteins to form a Schiff base, and the saccharides further into ketoamines 
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(Amadori products). Irreversible cross-links are formed by a further reaction known as 
Maillard reaction. An overview of this reaction scheme is shown in figure 7. The rate of AGE 
formation depends on the saccharides involved; for example, fructose is approximately seven 
times more reactive than glucose [128]. 
AGE affects the mechanical characteristics of collagen such that it becomes stiffer and less 
elastic [129]. These changes can be harmful, depending on the location of collagen. For example, 
loss of elasticity in vascular walls could lead to an increased blood pressure [130], tendons could 
become less viscoelastic and stiffer [131-133]; bone tissue could lose plasticity and toughness [134, 
135], and cartilage could become more fragile [136]. The amount of pentosidine (an AGE product) 
increases linearly with age in dura mater, and is also increased in diaphysial femurs; in both 
tissue types the amount of pentosidine increases 4-5 fold from the age of 10 to 80 [137, 138].
Collagen AGE can be analyzed with mass spectrometry [139, 140]. Holte et al. took biopsies of 
the tissue of interest, and cleaved proteins into amino acids [139]. Eight different AGEs were 
measured with a triple quadrupole mass spectrometer. These AGEs were present in the pmol/
mg range. Mikulikova et al. added AGEs to collagen in vitro by incubation of collagen with 
different sugars [140]. After incubation, collagen was reduced with mercaptoethanol, and 
cleaved into peptides by addition of CNBr followed by addition of trypsin. Samples were 
analyzed with CE-MS/MS and HPLC-MS/MS. Collagen peptides with AGE were identified with 
CE-MS/MS and with HPLC-MS/MS, whereby HPLC-MS/MS was more sensitive.
Figure 7. Overview of AGE formation in proteins. GOLD, MOLD, DOLD: glyoxal-, methylglyoxal-, and 
3-deoxyglucosone-derived lysine dimers.
- 31 -
2
II-B-7. Cross-linking
Enzymatic cross-linking is initiated by oxidation of lysine into allysine or hydroxyallysine. 
The aldehyde group is highly reactive, and reacts easily with nearby collagen lysines. In 
contrast to the hydroxylation of proline and lysine, this modification occurs outside the cell 
in the ECM. A flow scheme of collagen cross-linking is shown in figure 8. The formation of 
cross-linking consists of several intermediate steps. Initially formed cross-links are immature 
and reversible. Further reaction with a third amino acid (trivalent cross-linking with a lysine 
or histidine) results in mature cross-links, which are irreversible. These cross-links are 
illustrated in the boxes at the right-hand side of figure 8 inside a double-edged box. The only 
reversible trivalent cross-link is present in dehydro histidinohydroxymerodesmosine (deH-
HHMD, single-edged box).
The type of cross-link formed is tissue-dependent. Skin and tendon contain mainly lysine-
derived cross-links, whereas bone, cartilage, and dentin contain mainly hydroxylysine-
derived cross-links. The amount of trivalent cross-links per mol of collagen differs among 
various tissue types. In skin it is 280 mmol/mol; in bone tissue 495 mmol/mol; in patellar 
tendon: 870 mmol/mol; and in articular cartilage 1800 mmol/mol [67].
O-linked glycosation and cross-linking can be present together on the same lysine. Lysines 
containing an immature cross-link have more often glucosylgalactosyl-hydroxylysine 
attached [126]. Mature cross-links more often contain galactosyl-hydroxylysine. It is assumed 
that the larger carbohydrates hinder cross-link maturation.
Collagen cross-links can be directly studied with, for example, collagen digestion and 
analysis of peptides that contain the cross-link with mass spectrometry. Eyre et al. showed 
the possibilities of such a method in the study of collagen cross-linkers [141]. The chemical 
structure of a specific collagen cross-link had remained unknown for two decades. With the 
aid of mass spectrometry, this cross-link was identified as sulfilimine, and it is present as 
S-lysyl-methionine and as S-hydroxylysyl-methionine [142].
Also, it has been shown indirectly that the collagen turnover in bone tissue can be monitored 
by measuring urine concentrations of pyridinoline (Pyr) and deoxypyridinoline (d-Pyr). 
Patients with bone fractures or osteoporosis showed a significant increase in the excretion 
of Pyr and d-Pyr [143]. The constant ratio between Pyr and d-Pyr indicates that bone tissue 
was the source of origin [143]. Pyridinoline-derived cross-links can be measured easily with a 
fluorescence detector, because pyridinoline is a natural fluorescent compound [144].
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Figure 8. A flow chart of the major cross-links in collagen type I. Double edged boxes indicate 
irreversible cross-linking while single edged boxes indicate reversible cross-linking. The roman 
numbers on the right-hand side indicate: I, dominant in normal tissue; II, dominant in collagen 
type I, located in the skin and cornea; III, dominant in skeletal collagen. L.H., lysyl hydroxylase; L.O. 
lysyl oxidase; t, telopeptide; hel, triple helix; ACP, aldol condensation product; deH, dehydro; HLNL, 
hydroxylysinonorleucine; DHLNL, dihydroxylysinonorleucine; HHMD histidinohydroxymerodesmosine; 
HHL, histidinohydroxylysinonorleucine; d-, deoxy; Pyr, pyridinoline; Prl, pyrrole. 
Figure 9. The chemical structures of the final collagen cross-link form.
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Couppe et al. have given a short overview on the effect of aging on the amount of collagen 
and cross-links present in tendons [145]. These authors measured collagen cross-links levels 
with HPLC-fluorescence and pointed out that the literature is inconsistent with respect to 
the effects of aging in animals and humans on the amount of collagen and collagen cross-
links present in tendon. It is not clear why these effects might differ; however, prior life-long 
training history might play a role.
II-C. FUNCTIONAL CHARACTERISTICS OF COLLAGEN
II-C-1. The collagen family
The previous section focused mainly at collagen PTM structures and cross-linking in relation 
to structural chemistry. In this section, the focus will be on the normal biological function 
of the various supramolecular structures inside the human body and in pathology. A 
complete overview of all collagen types is given in table 4; an overview of different types of 
supramolecular structures is shown in figure 10. 
All collagen types in the collagen family contain a triple helix. The size of the triple-helix 
domain with respect to the total collagen length can vary from 96% (collagen type I) to less 
than 10% (collagen type XII). The length of a collagen domain varies from 75 nm (collagen type 
XII) up to 425 nm (collagen type VII) [146]. However, the triple-helix structure is not restricted 
to collagen; non-collagen proteins (e.g. Emilin, Ficolins 1, 2, and 3) show also collagen-like 
domains (Gly-Xaa-Yaa pattern; see [147]). For visualization of the fibers, see van der Rest et al. [22].
Table 4. Molecular composition of collagen triple helices in various tissues.
Type Class Triple helix composition Tissue distribution
I Fibril-forming [α1(I)]2 α2(I)
Abundant and widespread; bone, dermis, tendon, 
ligaments, cornea
II Fibril-forming [α1(II)]3 Cartilage, vitreous body, nucleus pulposus
III Fibril-forming [α1(III)]3
Skin, vessel wall, reticular fibers of most tissue (lungs, 
liver, spleen, etc.)
IV Basement membrane 
[α1(IV)]2 α2(IV)
Basement membranesα3(IV) α4(IV) α5(IV)
[α5(IV)]2 α6(IV)
V Fibril-forming 
[α1(V)]3
Widespread: lung, cornea, bone, placenta, fetal 
membranes; together with type I collagen
[α1(V)]2 α2(V)
α1(V), α2(V), α3(V)
VI Microfibrillar 
α1(VI),α2(VI), α3(VI) Widespread; dermis, cartilage, placenta, lungs, vessel 
wall, intervertebral discα1(VI),α2(VI), α4(VI)
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Table 4 continued.
Type Class Triple helix composition Tissue distribution
VII Anchoring fibrils
[α1(VII)]3 Skin, bladder, dermal-epidermal junctions; oral 
mucosa, cervix[α1(VII)]2 α2(VII)
VIII
Hexagonal network-
forming
[α1(VIII)]3
Widespread; dermis, brains, heart, kidney, endothelial 
cells, Descemet’s membrane
[α2(VIII)]3
[α1(VIII)]2 α2(VIII)
IX FACIT α1(IX) α2(IX) α3(IX) Cartilage, vitreous humor, cornea
X Hexagonal network-
forming
[α1(X)]3
Hypertrophic cartilage
[α3(X)]3
XI Fibril-forming α1(XI) α2(XI) α3(XI) Cartilage, vitreous body, intervertebral disc
XII FACIT [α1(XII)]3 Perichondrium, ligaments, tendon, dermis
XIII MACIT [α1(XIII)]3
Epidermis, hair follicle, endomysium, intestine, 
chondrocytes, lungs, liver, eye, heart
XIV FACIT [α1(XIV)]3
Widespread; bone, dermis, tendon, vessel wall, 
placenta, lungs, liver, cartilage
XV Multiplexins [α1(XV)]3
Fibroblasts, smooth muscle cells, kidney, pancreas, 
testis, capillaries
XVI Multiplexins/FACIT [α1(XVI)]3 Fibroblasts, amnion, keratinocytes, dermis, kidney
XVII MACIT [α1(XVII)]3
Dermal-epidermal junctions, hemidesmosomes in 
epithelia
XVIII Multiplexins [α1(XVIII)]3 Lungs, liver, basement membrane
XIX FACIT [α1(XIX)]3 Human rhabdomyosarcoma, basement membrane
XX FACIT [α1(XX)]3
Corneal epithelium, embryonic skin, sternal cartilage, 
tendon
XXI FACIT [α1(XXI)]3 Blood vessel wall, stomach, kidney
XXII FACIT N/A Tissue junctions
XXIII MACIT N/A Heart, retina
XXIV Fibril-forming N/A Bone, Cornea
XXV MACIT N/A Brain, heart, testis
XXVI FACIT N/A Testis, ovary
XXVII Fibril-forming N/A Cartilage
XXVIII N/A N/A Dermis, sciatic nerve
FACIT, fibril-associated collagen with interrupted triple helices; MACIT, membrane-associated collagen with 
interrupted triple helices; Multiplexin, multiple triple-helix domains and 
Interruptions; N/A, not available [21, 148, 149].
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Figure 10. Eight different supramolecular structures which can be formed by members of the collagen 
family can be distinguished. a) Fibril forming collagen types. b) Fibril-associated collagen types with 
interrupted triple helices (FACITs), FACITs are located at the surface of fibrils. c) Hexagonal networks. 
d) Basement membrane formed by collagen type IV. e) Beaded filaments formed by collagen type VI. f ) 
Anchoring fibrils for basement membrane formed by collagen type VII. G) Collagen types containing 
transmembrane domains. h) Collagen type XV and XVIII. I) proteins containing triple-helical collagenous 
domains.[21] Reprinted with permission from the authors, 2004 Elsevier.
II-C-2. Collagen-related diseases
Collagen is involved in many biological processes. Aberrant collagen turnover, genetic 
mutations, or aberrant PTMs can result in the collagen-related diseases shown in table 
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5. Although this table does not list tumors, collagen is also strongly involved in tumor 
progression and metastasis. In tumor development, there is probably an important role 
for the ECM. It has been proposed that the ECM can act as a tumor suppressor as long as it 
remains in its ’natural shape’, and a tumor promoter activity if the ’natural morphology’ 
is lost [150]. The ’natural morphology’ of the ECM will change over time, for example, due to 
inflammation, growth factors, and accumulated damage [150]. In breast cancer, Ma et al. have 
shown upregulation of the gene expression of 23 collagen genes and of 94 other ECM genes 
[151]. Furthermore, Naba et al. and van Huizen et al. have shown that the collagen composition 
of colorectal liver metastasis is significantly different from that of healthy liver tissue [26, 152].
Table 5. Overview of collagen-related diseases.
Collagen type Disease
I Caffey disease
EDS type I, II, VIIA, VIIB
OI type I, II, III, IV
Osteoporosis
II Achondrogenesis, type II or hypochondrogenesis
Avascular necrosis of the femoral head
Legg-Calve-Perthes disease
Osteoarthrosis
SED congenita
Several (chondro)dysplasias
SMED Strudwick type
Stickler syndrome, type I
III Arterial aneurysms
EDS type IV
IV Alport syndrome
Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps
Brain small vessel disease with or without ocular anomalies
Hematuria
Porencephaly type 1, 2
Retinal arteries, tortuosity
Schizencephaly
V EDS type I and II
VI Bethlem myopathy
Ullrich congenital muscular dystrophy 1
Dystonia 27
VII Epidermolysis bullosa dystrophica, dystrophic forms
IX Intervertebral disc disease
Multiple epiphyseal dysplasia
Osteoarthrosis
Stickler syndrome, type IV, V
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Table 5 conitnued.
Collagen type Disease
X Chondrodysplasia
Schmid metaphyseal chondrodysplasia
XI Deafness
Fibrochondrogenesis type I
Marshall syndrome
Non-syndromic hearing loss
Osteoarthrosis
Several mild chondrodysplasias
Stickler syndrome type II
XII Bethlem myopathy 2
XIII Myasthenic syndrome, congenital, 19
XVII Epidermolysis bullosa
Epithelial recurrent erosion dystrophy
XVIII Knobloch syndrome
XXV Fibrosis of extraocular muscles, congenital, 5
XXVII Steel syndrome
OI, osteogenesis imperfecta; EDS, Ehlers-Danlos syndrome. [153] and omim.org (accessed 20-11-2017).
II-C-3. Collagen remodelling
The first step in collagen remodeling is the enzymatic cleavage by matrix metalloproteinases 
(MMPs); see Table 6 for an overview of all MMPs and the collagen types and other substrates 
they cleave. Remodeling is an important process in inflammation, wound healing, tumor 
proliferation, and exercising [154-156]. Besides collagen, MMPs can also degrade other ECM 
components. MMPs cleave collagen at specific points in the triple helix; i.e., at roughly three-
quarters of the length of the helical domain in collagen types I, II, and III. More specifically, 
collagen type I alpha 1 is cleaved at site Gly775-Ile776, and type 1 alpha 2 is cleaved at site Gly775-
Leu776 [157]. Zhen et al. used mass spectrometry to identify novel cleavage products of various 
MMP types in cartilage [158]. The produced peptides could be of further interest for diseases in 
which collagen turnover takes place.
Table 6. The MMP family, the collagen types they cleave and other substrates [159-161].
Enzyme groups MMP Collagen type Other substrates
Collagenases
Collagenase-1 MMP-1 I, II, III, VII, VIII, X, XI Gelatin
Collagenase-2 MMP-8 I, II, III, VII, VIII, X Aggrecan, gelatin
Collagenase-3 MMP-13 I, II, III, IV, VI, X, XIV Gelatin
Gelatinases
Gelatinase A MMP-2 I, II, III, IV, V, VII, X Gelatin
Gelatinase B MMP-9 IV, V, XI, XIV Gelatin
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Table 6 continued.
Enzyme groups MMP Collagen type Other substrates
Stromelysins
Stromelysin-1 MMP-3 II, III, IV, VII, IX, X, XI Gelatin
Stromelysin-2 MMP-10 III, IV, V Laminin, fibronectin, elastin
Stromelysin-3 MMP-11 IV Laminin, fibronectin, aggrecan
Matrilysins
Matrilysin-1 MMP-7 I, IV Laminin, fibronectin, gelatin
Matrilysin-2 MMP-26 IV Fibronectin, fibrinogen, gelatin
Membrane Type MMPs
MT1-MMP MMP-14 I, II, III, Gelatin, fibronectin, laminin, proMMP-2
MT2-MMP MMP-15 Gelatin, fibronectin, laminin, proMMP-2
MT3-MMP MMP-16 III Gelatin, fibronectin, laminin
MT4-MMP MMP-17 Fibrinogen, fibrin
MT5-MMP MMP-24 Gelatin, fibronectin, kaminin
MT6-MMP MMP-25 IV Gelatin
Others
Macrophage metalloelastase MMP-12 I, IV Elastin, fibronectin
MMP-19 I, IV Aggrecan, elastin, fibrillin, gelatin
Enamelysin MMP-20 Aggrecan
XMMP MMP-21 Aggrecan
MMP-23 Gelatin, casein, fibronectin
CMMP MMP-27 Unknown Unknown
Epilysin MMP-28 Unknown Unknown
After cleavage of a collagen triple helix, the triple helix will start to unfold and denaturate to 
increase accessibility for other enzymes to further cleave collagen [162]. For a more complete 
overview on the regulation of MMPs and the reaction mechanism, the review by Ala-aho et al. 
[162] is recommended. With hydrogen-deuterium exchange mass spectrometry, the sites where 
collagen type I binds with MMP-1 have been mapped [163, 164].
The triple helix of collagen is embedded in supramolecular structures that are cross-linked 
by enzymatic and non-enzymatic initiated cross links to thereby create a structure that is 
difficult to degrade. Thus, collagen in the human body has a long half-life, which in certain 
tissue types can, surprisingly, exceed a human life time. Yet, the half-life varies strongly 
between different organs: from 15 years in skin, 117 years in cartilage and to up to 95-215 years 
in vertebrate discs [165, 166]. Collagen half-life times in rats have been determined with isotope-
ratio mass spectrometry: 45 days in muscle; 74 days in skin; and 244 days in gut [167]. In these 
rats, the half-life times of collagen type III were shorter than those of collagen type I [167]. 
Isotope-ratio mass spectrometry also revealed that the core of the Achilles tendon has almost 
no turnover after an individual’s growth has stopped [168]. Furthermore, isotope ratio mass 
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spectrometry revealed that damaged cartilage from osteoarthritis did not show additional 
regeneration [169]. 
Apart from the long-term collagen turnover, also the short-term collagen turnover can be 
studied with mass spectrometry. Wilkinson et al. showed the possibility to detect day-to-
day muscle protein synthesis and collagen turnover by administering deuterated water to 
eight healthy young men and have them perform one-legged resistance exercises. Deuterated 
water present during protein turnover will be incorporated in the newly formed proteins, 
forming heavy isotope labelled proteins. The one-legged resistance exercises stimulate extra 
muscle grow. The turnover of the growing muscle increases and more deuterated water will 
be incorporated in comparison to the non-exercised leg. The different amounts of heavy 
isotope labelled proteins between both legs can be analysed in biopsies with isotope ratio 
mass spectrometry [170]. Exercised legs showed a larger increase in deuterium-labelled collagen 
than did the non-exercised legs.
Using ELISA Karsdal et al. analysed collagen fragments in rat blood over the course of one year 
and found that the collagen turnover was strongly related to age [171]. The turnover in collagen 
types I and type II showed a strong decrease; that collagen type III increased over the first 
month and then stabilized; that of collagen type IV increased over time; and the turnover of 
collagen types V and VI remained fairly constant [171]. This study implicates that age can be a 
confounding factor when a collagen-related disease is studied.
III. TECHNIQUES TO ANALYZE COLLAGEN
Several techniques are available to study collagen. The three most commonly used techniques 
are mass spectrometry, circular dichroism spectroscopy, and staining, both chemical staining 
and immunological. These techniques will be discussed in this section, preceded by a short 
overview of other possible techniques to analyze collagen.
III-A OVERVIEW OF TECHNIQUES
Apart from mass spectrometry, circular dichroism, and staining, other techniques have been 
used to analyze collagen. X-ray based techniques, applied as early as the 1940s [172], determine 
the collagen triple helix structure [173]. Electron microscopy, also applied since the 1940s [174] 
visualizes the collagen fibril size and three-dimensional organization [175]. Likewise, second-
harmonic generation (SHG) can also be used to visualize and study collagen fibers with a 
resolution of approximately 1 µm [176, 177]. Enzyme-linked immunosorbent assay (ELISA) is 
another way to quantify collagen in serum [178]. 
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III-B. MASS SPECTROMETRY
The first publication on collagen and mass spectrometry dates back to 1970 [179]; this article 
describes the analysis of collagen cross-linking products with GC-MS. From then onwards, the 
number of publications on collagen and mass spectrometry steadily increased. In the period 
2013-2018, between 100 and 150 articles were published annually. This rise in publication rate 
went hand in hand with the developments in the field of mass spectrometry, which made it 
possible to study (large) biomolecules such as peptides and proteins. The most important 
developments were the invention of electrospray ionization (ESI; Nobel Prize 2002, J.B. Fenn) 
[180] and matrix-assisted laser desorption/ionization (MALDI; Nobel Prize 2002, K. Tanaka) 
[181]. Other developments in the fields of bioinformatics and engineering have also been 
valuable for the analysis of biomolecules as they have increased the overall performance 
(e.g. sensitivity, speed, versatility) of mass spectrometry. For the reader interested in the 
development of mass spectrometry and proteomics we recommend the following articles: [182-
186]. All these developments have made it possible that thousands of proteins and a multitude 
of peptides can be identified in a single measurement [187]. Below, an overview is given of the 
use of mass spectrometry for the study of collagen. 
III-B-1. Sample processing for mass spectrometry analysis
Collagen can be analyzed in a wide variety of liquid (e.g. urine [11], serum [188], CSF [189]) and solid 
biomaterial (e.g. bone [190], tissue [152] with different mass spectrometry applications such as 
bottom-up proteomics [26], top-down proteomics [191], targeted analysis [12], MALDI-imaging [192], 
hydrogen-deuterium exchange [164], and isotope ratio mass spectrometry [170].
The most standard approach for proteomic analysis of collagen (bottom-up-, or shotgun 
proteomics) in tissue is the solubilization of proteins followed by reduction, alkylation, and 
digestion with an enzyme (often trypsin). Peptides produced by such a sample preparation 
method are online separated on a liquid-chromatography system (LC) followed by MS/MS 
identifications [193-195]. This standard approach is already suitable to study collagen, and van 
Huizen et al. identified with this approach 1,137 unique collagen peptides that belong to 22 
different alpha chains in liver and colorectal liver metastasis [26].
Hard tissue such as bone and cartilage tissue, where collagen is highly abundant, requires 
a harsher extraction method than for soft tissue or cells. Addition of hydrochloric acid and 
heating is required to extract collagen from bones. This method works very well, and can, for 
example, be used to distinguish bone materials from different animal species with MALDI-
TOF [196].
Another source of collagen is provided by stable isotope labeling by amino acids in cell 
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culture (SILAC). This method to label collagen produced by cells in culture enables to quantify 
specific collagen types, turn-over rates, total collagen levels, and collagen PTMs [197]. Another 
method is culturing of cells in Petri dishes followed by removal of cells and extraction of 
ECM proteins, including collagen [198]. Taylor et al. cultured mouse primary osteoblasts on 
coverslips [199]. After the culture period, the cells were removed (decellurization) and the 
produced ECM proteins remained behind on the coverslip. After a clean-up step of the ECM 
proteins, the coverslip with ECM proteins was inserted into a time of flight - secondary ion 
mass spectrometer (TOF-SIMS) for analysis. Collagen levels were indirectly analysed by 
measuring picrosirius red (staining with picrosirius red is discussed in more detail in III-D-1). 
The picrosirius red levels, and consequently collagen levels, differed under different culture 
conditions.
Enrichment of the sample for collagen leads to a higher number of identified peptides. There 
are several methods to enrich samples for collagen, of which two are especially suitable 
for tissue. One consists of decellularization), whereby ECM structures remain behind. The 
decellularized tissue can be further digested and analyzed with bottom-up mass spectrometry 
[200, 201]. In the other method, ECM proteins are extracted from tissue. Naba et al. showed the 
capability of such an extraction method to extract collagen from tissue and identify up 
to 32 different alpha chains in colon tissue [152, 202]. This extraction method is based on the 
extraction of proteins from different cell compartments (cytoplasm, nucleus, membrane, 
and cytoskeleton), whereby ECM proteins are left behind. These can be further digested and 
analyzed with mass spectrometry.
A disadvantage of protein digestion is the loss of spatial resolution, which can be prevented, 
however, with MALDI imaging mass spectrometry [203]. This approach will be discussed in more 
detail in III-D-3. Currently a resolution in the lower µm range can be achieved [204]. To image 
proteins in tissue sections with MALDI imaging, proteins are cleaved into peptides on a glass 
slide. These peptides can be ionized and subsequently visualized by a mass spectrometer.
Apart from enrichment of whole proteins, enrichment of peptides after protein digestion 
is also possible. Fractionation allows for a relative deeper view on the proteins present in a 
clinical sample. Roughly two ways of fractionation can be distinguished: online separation 
on an LC system where fractions are collected automatically and online measured with mass 
spectrometry, and off-line separation with, for example, disposable columns (e.g., ZipTips) or 
off-line automated affinity separation (e.g., separation of PTM-containing peptides).
Furthermore, the use of different enzymes to cleave proteins into peptides and the use of 
different fragmentation techniques of peptides in the mass spectrometer allow for the 
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mapping of hydroxyproline, hydroxylysine, and O-glycosylation in collagen [70-72]. Basak et al. 
used trypsin, Glu-C, and LysC to cleave proteins into peptides. In a part of the sample set, 
glycosylations were removed with PNGase F. Peptides were fragmented with both CID and 
ETD in an LTQ Orbitrap Velos, and also on a Q Exactive with HCD fragmentation. The use 
of different enzymes and fragmentation techniques resulted in a sequence coverage of 81.5% 
and 85% of mouse EHS tumor COL4A1 and human lens capsule COL4A1, respectively. Song et 
al. performed protein digestion by use of GluC and trypsin, and performed CID, HCD, and 
ETD fragmentation in an LTQ Orbitrap Velos. This approach resulted in a sequence coverage 
of 90% (excluding signal-, pro-, and C-telopeptides) of pepsinized immunization-grade 
bovine COL2A1. Yang et al. performed digestion with GluC, chemotrypsin, trypsin, and a 
combination of GluC and AspN. Digestion was followed by LC-MS analysis, whereby peptides 
were fragmented with HCD and ETD, and a combination of MS2 and MS3 was applied. This 
protocol resulted in a 94% sequence overlap for collagen alpha-1(V) from bovine placenta and 
a 90% sequence overlap for human collagen alpha-1(V).
Collagen cross-linking can be analyzed with mass spectrometry in tissue [141, 205, 206]. Preparing 
samples for mass spectrometry analysis of collagen cross-links is commonly done by 
reduction of the sample with sodium borohydride followed by a clean-up step (e.g. filtration 
with a cellulose column). After the clean-up step or reduction step, the sample is hydrolyzed 
by addition of hydrochloric acid. After removal of the hydrochloric acid the sample is ready 
for LC-MS analysis [205, 206]. Eyre et al. give an overview of several methods to analyze collagen 
cross-links in bone and tendon. They also address the analysis of cross-link markers in urine, 
which markers can detect bone cancer with good accuracy. The methods described are based 
on mass spectrometry measurements, immunoassays, and fluorescence measurements [141].
Besides the digestion of collagen, naturally occurring collagen peptides can also be detected. 
Naturally occurring peptides can be purified with high molecular weight filters and a 
desalting step [207]. An alternative, more convenient way is the use of a C18 column for the 
clean-up of urine to perform qualitative (shotgun proteomics) and quantitative (targeted 
analysis) analysis of natural occurring collagen peptides [208, 209].This method allows detecting 
naturally occurring peptides with mass spectrometry also in serum [188]. Naturally occurring 
peptides can be analyzed in both a bottom-up (semi-quantitative) and in a targeted way 
(absolute quantification with stable-isotope labelled peptides).
Most of the above-described methods use an ESI-source connected to a LC. Less commonly 
used is capillary electrophoresis (CE) for chromatographic separation. Equipped with an UV 
detector, CE could separate collagen peptides and detect them directly [210-212] or via an online 
connection to a mass spectrometer. Many publications describe analyzing collagen in urine 
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with CE-MS [207, 213-216]; collagen was often part of a biomarker panel to predict the presence 
of a disease (e.g. diabetes, kidney diseases). Urine was prepared for CE-MS by addition of urea, 
ammonium hydroxide, and SDS.
Drube et al. added ureum, NH4OH, SDS to urine, and removed the proteins with a 20 kDa filter 
[215]. The filtered samples were then applied to a desalting column to remove urea, electrolytes, 
and salt. The purified material was concentrated and injected into the CE-MS. This protocol 
is almost identical to that used by Broker et al. for the measurement of collagen NOPs in 
urine with LC-MS [11]. Molin et al. compared the performance of CE-MS and that of MALDI-MS 
to detect chronic kidney disease; collagen in urine was one the most significant markers of 
chronic kidney disease, irrespective of the system used [216].
III-B-2. Collagen stoichiometry
The stoichiometry of different alpha chains in a triple helix or the composition of 
supramolecular structures can be analyzed with mass spectrometry. Onnerfjord et al. showed 
that the collagen composition in cartilage collected from eight different locations in the 
body differed per location [217]. The collagen had been extracted with the use of hydrolysis 
induced by hydrochloric acid. Samples were reduced, alkylated, and digested with trypsin. 
Samples were combined using iTRAQ (isobaric tag for relative and absolute quantitation). 
Another example is the composition of collagen type IV in different locations, reported by 
Uechi et al. In-gel digestion of three different parts of the eye (blood vessels, inner limiting 
membranes, and lens capsules) followed by intensity-based absolute quantification (iBAQ) 
mass spectrometry analysis, revealed that the collagen type IV composition and alpha chain 
ratios differed between the tissues types [218]. Dreisewerd et al. showed that it is possible to 
ionize complete collagen alpha chains –and even dimers, trimers, up to hexamers– with 
an IR-MALDI-TOF and UV-MALDI-TOF [191]. The measurement of mono- (α), di- (β), tri- (γ, 
triple helix), tetra- (τ), and hexamers (η) leads to complex mass spectra. Examples shown 
by these authors indicate that overlapping masses exist for: α+/ γ3+/ β2+, 2α+/β+, and 3α+/ γ +. 
To prevent overlapping molecular masses, size-exclusion chromatography was performed; 
however, overlapping masses were still present after size-exclusion chromatography. Also, 
the mass of a triple helix is not a single peak but a broad envelop with varying amounts of 
hydroxylations and glycosylations; the envelop was determined to be 283,300 ± 1,300 Da for 
collagen type I. High-resolution capabilities are required to separate all different isotopes, 
differently-charged species with a similar mass, and various numbers of hydroxylations and 
glycosylations. For example, an alpha chain is approximately 100 kDa when α+/ γ3+ are present, 
and a resolution of >33,000 is needed to separate the two masses. Such a resolution can be 
easily obtained in state-of-the-art high-resolution mass spectrometers.
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III-B-3. The role of collagen in dating of bone 
Collagen has a high in vivo half-life, sometimes even exceeding the life-time of the organism 
(see II-C-3 Collagen remodelling). Collagen in bone, for example, is stable up to 10,000 years 
and beyond [219], which implies that collagen can be used to date bones. Collagen bone dating 
can be performed in two different ways i.e. isotope ratio analysis and D/L racemization of 
amino acids [220]. For both analyses, collagen extraction is required; collagen can be extracted 
in different ways. A general procedure starts with cleaning of the bones, taking a sample of 
ca. 0.5 - 1 g, and dissolve this in HCl. Humics can be removed with addition of NaOH or rinsing 
the sample to a neutral pH, followed by gelatinization under acidic and heated conditions. 
Finally, the sample is filtered and analyzed with mass spectrometry. Jorkov et al., Piotrowska 
et al., and Cersoy et al. have compared several slightly different protocols that in essence are 
similar to the general procedure described above; the various protocols gave comparable 
results [221-223].
 
The prepared samples can be analyzed with acceleration mass spectroscopy (AMS). The 
strength of AMS is the ability to measure isotopes, and even distinguish between isobars, 
for example, nitrogen-14 and carbon-14. A review by Kutschera gives a good overview of the 
workings and applications of AMS [224]. Samples can also be measured with isotope-ratio mass 
spectrometry (IR-MS), which are sector instruments. The website www.planetisotopes.com 
provides an overview of the various instruments used in IRMS and their applications.
 
Quality of the bone tissue sample is determined by analyzing the total collagen content, the 
nitrogen content, carbon/nitrogen ratio, carbon-13, and nitrogen-15 levels. Carbon-14 levels 
relative to carbon-12 levels indicate the age of the original sample. For example, Hublin et 
al. showed that 40 bone samples from different locations in the Grotte du Renne (in France) 
were between 29,000 – 43,000 years old [225].
However, there are a few pitfalls in the analysis of isotope ratios in collagen. The most 
important one is the sample preparation; any contamination of younger organic material 
will affect the isotope ratios in the sample [226]. Because recent material will have a different 
isotope ratio than the sample of interest, it is key to clean the tissue prior to analysis as well as 
possible, and also during sample preparation take care not to contaminate the sample under 
investigation.
III-B-4. Collagen-based animal identification and classification
The field that identifies animal bones with mass spectrometry is called ’Zooarchaeology by 
mass spectrometry’ (ZooMS). Collagen is an ideal protein to study with ZooMS, because it is 
highly stable over time [219] and is highly conserved between different species; a higher level of 
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conservation is observed in more closely related species. Welker et al. showed the clustering 
of South American animals based on COL1A1 and COL1A2 primary amino acid sequences [190]. 
Buckley et al. showed similar results for 47 different mammals and 4 types of birds [196]. The 
analysis described by Buckley et al. only requires 1 mg of bone tissue, which is demineralized 
with hydrochloric acid, and digested with trypsin. Digestion was followed by a clean-up step 
done with a C18 ZipTip. The purified peptides were analyzed with a MALDI-TOF and eventually 
92 collagen peptides were found to sufficiently distinguish between the different animals. 
Another publication by Buckley and co-workers shows the possibility to distinguish between 
44 different species and sub-species of sheep and goats [227]. Collagen peptides were collected 
by incubating bone with hydrochloric acid, followed by SPE separation and measurement 
with a MALDI-TOF. 
 
This principle can also be used to identify the animal source(s) of, for example, gelatin 
[228, 229], leather [230], and meat. Zhang et al. demonstrated the possibility to detect unique 
collagen peptides in a trypsin digested gelatin mixture of bovine and porcine [228]. Zhang et 
al. demonstrated that difficulties can arise in the identification collagen primary structures 
because Gly-Ala-4Hyp is a structural isomer of Gly-Ser-Pro; therefore they recommend manual 
inspection of the MS2 spectra. Grundy et al. compared the identification of species with mass 
spectrometry with current PCR and ELISA techniques and showed that mass spectrometry 
was comparable to ELISA; ELISA and mass spectrometry both outperformed PCR [229].
III-C. CIRCULAR DICHROISM SPECTROSCOPY 
III-C-1. Circular Dichroism Spectroscopy
Collagen has characteristic properties with respect to refraction and absorption of visible 
light. First, collagen is birefringence, which means that the refraction index of light of the 
same wavelength depends on the polarization direction. Second, collagen shows circular 
dichroism, which means that the absorption of light of a certain wavelength is dependent 
on the polarization. Both properties are characteristic for the triple helix. Circular dichroism 
spectroscopy (CD) is used to study secondary structures of proteins by the detection of the 
difference in absorbance between left- and right-handed circular polarized light. 
Furthermore, CD is commonly used to study the Tm of collagen triple helices. When the 
triple helical structure is lost, circular dichroism also disappears. Therefore, (un)folding of a 
triple-helix can be monitored over a temperature gradient. However, triple helix (un)folding 
does not occur instantaneously but takes place over a temperature range in solution. The 
(un)folding Tm can also be influenced by solvents, salts, collagen concentration, amino acid 
sequence, and PTMs. We recommend for more detailed information the article by Mizuno et 
al. on the effect on the Tm by different temperature gradients and collagen concentrations 
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[231] and that by Woodlock et al. regarding the effect on the Tm by the pH and different 
concentrations of various salts [232].
The Tm of specific tripeptides or the effect of PTMs of interest can be tested with ‘guest 
peptides’. Guest peptides are short synthetic peptides that are used to test a hypothesis. 
Because the experimental design differs slightly among the various publications [48, 82, 233], 
only relative comparisons of the Tm can be made. Besides analyzing guest peptides, full triple 
helices can also be analyzed [61, 62].
Ramshaw et al. have analyzed the Tm of 34 different tripeptides [48], which might be just a small 
step in light of the 400 possible tripeptides. Nevertheless, these 34 different tripeptides cover 
roughly 50 % of the helical region. The most stable tripeptides contain amino acids capable 
of ion-ion interactions. Furthermore, the position (Xaa or Yaa) of an amino acid influences 
the ability to form hydrogen bounds and interaction with the peptide backbone [234-237]. This 
positional effect can result in Tm differences of 25oC and can cause locally micro-unfolding. 
Tripeptides with a high stability are, in general, more numerous than tripeptides with a low 
stability [48, 238, 239].
III-C-2. Possible mass spectrometry alternatives for CD
Circular dichroism spectroscopy is a well-established technique to determine the Tm of 
collagen as a whole but also of small guest peptides to study specific changes in the Tm as 
a function of change in the amino acid sequence. These experiments can also be performed 
with hydrogen/deuterium exchange mass spectrometry (HDX-MS). For the reader interested 
in HDX-MS we recommend the review by Masson et al. [240].
 
HDX-MS is also suitable to detect collagen micro-unfolding, which is supposed to occur at 
specific locations in collagen [241-243]. Collagen micro-unfoldings in the triple helix can occur as 
a consequence of a local low Tm in the helix. At those micro-unfoldings, hydrogens might be 
exchanged for deuterium; by subsequent lowering of the Tm, the micro-unfoldings are closed 
and the deuterium will be captured. The captured deuterium causes a mass shift which can be 
measured with mass spectroscopy.
III-D. STAINING
III-D-1. Picrosirius red
Apart from the difference in polarized light absorption, collagen triple helices are also 
birefringent. Birefringence is the optical property of a compound whereby the refractive 
index depends on the polarization direction. With polarization microscopy, collagen can 
be studied in tissue sections. The collagen becomes better visible with an increased fiber 
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thickness, especially for collagen types I and type III. Picrosirius red staining can enhance 
the birefringent properties of collagen fibers. This technique has been known since 1979 
[244] and is often used in the pathological analysis of tissue. This staining technique is highly 
specific for collagen; the staining itself is not specific for collagen, but the synergistic effect 
of combining it with birefringence makes it so. The compound that enhances birefringence 
is ’direct red 80’ (see figure 11). The acidic groups of this compound bind with basic groups of 
collagen and align along the fibers and this binding enhances the birefringence properties of 
collagen. ‘Direct red 80’ has a high extinction coefficient that allows detecting collagen levels 
as low as 5.76 µg collagen/mg protein in tissue [245]. The observed color depends mainly on the 
fiber thickness and ranges from green (< 0.8 µm) to yellow, orange and red (1.6 - 2.4 µm); also 
fiber packing density and alignment of the fibers influence the color (from green to red) [246]. 
 
In addition to polarized light, picrosirius red staining can also be visualized with fluorescence 
microscopy, which is more sensitive, but does not show differences in fiber thicknesses [247].
Figure 11. Direct red 80, active compound in picrosirius red.
III-D-2. Other staining techniques
Apart from picrosirius red staining, other techniques can be applied to stain collagen. For 
example, Masson’s trichrome stains collagen blue, nuclei black, and cytoplasm red. Van 
Gieson’s picrofuchsin stains several tissue types, muscles and cytoplasm yellow-brownish, 
collagen red, red blood cells yellow, and cartilage pink.
In theory, a specific and sensitive staining technique is immunohistochemistry (IHC), which 
makes use of an antibody that binds to the protein of interest. Karagiannis et al. determined 
the proteomic signature of the desmoplastic invasion front during colorectal cancer 
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metastasis [248]. They observed a large difference in the expression pattern of collagen type XII 
and that of type III (figure 12).
Figure 12. Immunohistochemically staining of collagen type XII (left) and collagen type III (right) at 
the invasion front of colorectal cancer. The black arrow in the left-hand panel indicates tumor budding; 
the demarcated cells line the invasion front.[248] Reprinted with permission from the authors, 2012 
Impactjournals.
III-D-3. Mass spectrometry – an alternative for staining?
The advantage of (IHC) tissue staining over mass spectrometry analysis is preservation 
of the spatial distribution. This allows determining co-localization and observing tissue 
morphology changes beyond the protein(s) of interest. Still, specific sample processing 
methods and desorption/ionization methods make mass spectrometry competitive with 
(immunohistochemistry) staining.
 
Selected subsections of tissue can be collected with laser-capture microdissection (LCM). 
These subsections can be as small as individual cells. The analysis of these tissue subsections 
makes it possible to select specific cell types, or stroma components and to identify with 
mass spectrometry more than 3,400 proteins [249]. The sample processing after LCM is similar 
to normal bottom-up proteomics [250]. Clair et al. described a method whereby tissue is 
selected with LCM, followed by sonication, and online trypsin digestion followed by mass 
spectrometry analysis, which only takes 50 minutes, in comparison to almost two workdays 
when overnight trypsin digestion is performed. Prior to LCM, staining of tissue is still 
necessary to select the area of interest, and assessment by a pathologist or an experienced 
researcher is needed to select the cells or structures of interest.
 
In MALDI imaging mass spectrometry (MALDI-IMS), direct analysis of the tissue of interest is 
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feasible without the need to stain, although staining is compatible with mass spectrometric 
analysis of collagen [251, 252]. Collagen can be detected in both FFPE tissue [253] and fresh frozen 
tissue [254]. MALDI-IMS is strongly limited by the low number of analytes measured per pixel 
and by the absence of separation techniques (such as liquid chromatography). It has been 
suggested to use MALDI-IMS to characterize tissue (molecular histology) and to select 
interesting areas with LCM [255] for further in-depth identification and analysis. Dilillo et al. 
described the analysis of tissue by MALDI-IMS on a polyethylene naphthalate (PEN) slide 
followed by LCM from the same PEN slide. In the MALDI-IMS measurement, the spatial 
location is determined by the various masses of molecules, and the identification is based 
on in parallel performed LCM followed by LC-MS/MS measurements in consecutive sections. 
To detect collagen in fresh frozen tissue, a tissue slice is placed on a glass slide, followed by 
drying, lipid removal, and subsequent matrix deposition. Extra steps are required for the 
analysis of FFPE with MALDI-IMS. Cazares et al. describe a heat-induced antigen retrieval step 
followed by in situ tryptic digestion.
 
These limitations do not inhibit the analysis of collagen with MALDI-IMS; see table 7 for an 
overview of collagen peptides observed with MALDI-IMS. Decellularization of tissue even 
further increases the number of ECM proteins and especially collagen identifications [192]. 
Direct identification of peptides with MALDI-IMS is not common practice; often tissue is also 
analyzed in parallel with LC-MS/MS to provide a list of peptides with accurate masses that are 
matched to the masses detected with MALDI-IMS. For the reader interested in the application 
of MALDI-imaging in pathology, the following review is recommended [256].
 
Apart from collagen, also collagen turnover related proteins are visible with MALDI-imaging. 
An example is MMP-11, which was validated by analysis of the zinc location in the tissue with 
laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) [257] which allows 
elemental imaging. Luptakova et al. analyzed with LA-ICP-MS the Na+/K+ ratio in rat brains [258].
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Table 7. Overview of MALDI-Imaging mass spectrometry analysis of collagen.
Collagen type Number of peptides Tissue Reference
COL6A3 1 Stenotic aortic valve (Human) [254]
COL1A1
COL1A2
COL3A1
COL4A1
COL4A2
COL4A3
COL4A4
COL4A5
COL5A1
COL5A2
COL6A1
COL6A2
COL6A3
COL12A1
30
25
20
7
14
2
2
2
5
2
12
9
33
2
Kidney (mouse)
Decellularized
[192]
COL1A1
COL6A2
1
1
Lymph node (Human) [259]
COL6A3 Whole protein Cardiac tissue [260]
PubMed was systematically searched with the following queries: 
1) (“MALDI imaging”) AND “collagen” (n=4 publications) = (“MALDI imaging mass spectrometry”) AND 
“collagen” = (“MALDI ims”) AND “collagen”
2) (“collagen”) AND “imaging mass spectrometry” (n=9 publications)
3) (“MALDI imaging”) AND “extracellular matrix” (n=6 publications)
The different search queries retrieved a number of overlapping publications; furthermore, not all articles covered 
imaging of collagen.
IV. CONCLUSIONS AND FUTURE PERSPECTIVES
Mass spectrometry is a very versatile technique that allows the study of the collagen amino 
acid sequence, PTMs, interactions with other proteins, as well as the qualitative analysis of 
collagen. In addition, differences in collagen types can be studied, but also differences in 
stoichiometry, and quantitative analysis.
Mass spectrometry can be applied in a wide variety of tissues and body fluids. Analyzing the 
characteristics and localizations of collagen PTMs remains technically challenging. However, 
the continuing improvements in hardware (increase in sensitivity, and new fragmentation 
techniques) and developments in sample preparation (new enzymes) will undoubtedly 
improve the characterization and localization of PTMs. 
The function of 4Hyp in alpha helices is well understood, but little is known about, for 
example, the in vivo hydroxylation rate and whether certain hydroxylation patterns are 
more prevalent. These knowledge gaps can potentially be filled through the use of mass 
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spectrometry. Likewise, more knowledge can be obtained about less-common PTMs, such 
as 3Hyp, which may be involved in the alignment of supramolecular structures, and which 
so far have hardly been studied with mass spectrometry. In addition, the substrate of prolyl 
3-hydroxylase could be further studied by synthesis of peptides, similar to the experimental 
approaches used for prolyl 4-hydroxylase and lysyl hydroxylase. The degree of hydroxylation 
could be addressed with mass spectrometry using a targeted assay. 5-Hydroxylysine can 
be O-glycosylated with galactose, or glucose-galactose. Hardly anything is known about 
collagen N-glycosylation, and mass spectrometry is capable of identifying glycans linked to 
collagen. The function of collagen O-glycosylation is largely unknown; it is assumed to affect 
fiber thickness and collagen cross-linking. The amino group of the side chain of lysine and 
5-hydroxylysine can be oxidized into a very reactive aldehyde functionality which initiates 
collagen cross-linking. Collagen PTM analysis is up to now based on a mixture of different 
triple helices. The PTM analysis of individual collagen triple helices is still a technical 
challenge.
The way in which a change in the primary amino acid sequence or the addition of PTMs effects 
the Tm can be analyzed with CD. Both variations have been shown to strongly influence the 
Tm; up to 15oC differences are described. The difference in Tm between different tripeptides 
allows the local unfolding of the triple helix, thereby making it accessible for enzymes. These 
experiments also showed that a single mutation in the amino acid sequence can prevent the 
folding or results in the misfolding of a triple helix, which is the case in e.g. osteogenesis 
imperfecta and Ehlers-Danlos. The location of the mutation influences the severity of the 
effect on the folding. The data obtained with CD should only be compared in a relative way, 
considering the different experimental settings (e.g., heating/cooling rate, guest peptide 
composition). As alternative to CD, which by now is a well-established technique and has 
proven its value, hydrogen/deuterium exchange in combination with mass spectrometry is a 
most interesting alternative.
Staining of collagen is an easy way to quickly assess collagen expression and possible 
pathological differences in tissues. Among other things, picrosirius red has been used for 
nonspecific staining of fibrous collagen types, of which mainly collagen types I and III will be 
stained. Specific collagen types have been stained with immunohistochemistry. Replacement 
of immunohistochemistry by MALDI-imaging mass spectrometry has been a topic of interest 
for the last two decades. The possibility to detect a large number of molecules simultaneously 
with good spatial resolution is intriguing. MALDI-imaging mass spectrometry has shown to 
be able to measure collagen peptides in tissue, which allows the imaging of, for example, 
fiber composition and distribution of hydroxylation patterns in tissue.
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The role of collagen in healthy tissue is of great interest, especially to better understand 
diseases where collagen is defective or lacking. Collagen has various biological functions that 
are crucial for the normal functions of tissue, such as: handling of physical stress, cell-cell and 
cell-matrix interaction, cell signaling, cell migration, hydration of tissue, and extracellular 
matrix tension by regulation of collagen fiber thickness. Inhibition of the normal functioning 
of collagen will often lead to a disease. Besides the diseases described in table 5, collagen is 
also involved in tumor growth and metastasis. During tumor growth, the invasion of healthy 
tissue by tumor cells results in a remodeling of the locally produced ECM. Tumors produce 
MMPs which can cleave collagen and other ECM proteins. Especially collagen types I, III, and 
IV provide a barrier which could prevent tumor invasion. During the cleavage of collagen, 
degradation products are produced which could be of interest for the detection of tumors. A 
better understanding of the complex modifications of collagen will give more insight in the 
various functions of collagen in the normal and diseased states.
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CHAPTER 4
Up-regulation of collagen 
proteins in colorectal liver 
metastasis compared with 
normal liver tissue
ABSTRACT
Changes to extracellular matrix (ECM) structures are linked to tumor cell proliferation and 
metastasis. We previously reported that naturally occurring peptides of collagen type I are 
elevated in urine of patients with colorectal liver metastasis (CRLM). In the present study, we 
took an MS-based proteomic approach to identify specific collagen types that are up-regulated 
in CRLM tissues compared with healthy, adjacent liver tissues from the same patients. We 
found that 19 of 22 collagen alpha chains are significantly up-regulated (P < 0.05) in CRLM 
tissues compared with the healthy tissues. At least four collagen-alpha chains were absent or 
had low expression in healthy colon and adjacent tissues, but were highly abundant in both 
colorectal cancer (CRC) and CRLM tissues. This expression pattern was also observed for six 
non-collagen colon-specific proteins, two of which (CDH17 and PPP1R1B/DARP-32) had not 
previously been linked to CRLM. Furthermore, we observed CRLM-associated up-regulation 
of 16 proteins (out of 20 associated proteins identified) known to be required for collagen 
synthesis, indicating increased collagen production in CRLM. Immunohistochemistry 
validated that collagen type XII is significantly up-regulated in CRLM. The results of this 
study indicate that most collagen isoforms are up-regulated in CRLM compared with healthy 
tissues, most likely as a result of an increased collagen production in the metastatic cells. 
Our findings provide further insight into morphological changes in the ECM in CRLM and 
help explain the finding of tumor metastasis–associated proteins and peptides in urine, 
suggesting their utility as metastasis biomarkers.
Reprinted with permission from The Journal of Biological Chemistry. 2019 Jan 4;294(1):281-
289. Copyright 2019 American Society for Biochemistry and Molecular Biology.
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INTRODUCTION
The collagen protein family is well-studied, having 8000+ publications annually over the 
last five years (based on PubMed index, July 2018). Despite the large number of annual 
publications, there is still a need to explore collagen and its functions. It is believed that 
deepening on the understanding of collagen will eventually lead to significant contributions 
in important fields such as cancer, fibrosis, and regenerative medicine [268].
 
It is well known that the loss of the normal structure of the extracellular matrix (ECM), 
including the major component collagen, has been associated with enhanced tumor 
proliferation [269, 270]. Tumor proliferation changes the function of collagen [271, 272] and it has been 
shown that these changes are dependent on changes of individual collagen levels, as shown 
by Nyström et al. for colorectal cancer (CRC) [273]. These changes have been suggested to play 
a role in chemoresistance and increased cell proliferation becoming a vicious circle. Naba 
et al. showed differences of ECM proteins in colorectal liver metastasis (CRLM) compared to 
healthy liver in an underpowered sample set (n=3) [152]. However, a sufficiently powered study 
regarding the concentration of specific collagen types in CRLM is lacking.
As a result of CRLM, it has been shown that, an upregulation of collagen can be observed 
in urine [208, 274] and plasma [178]. Increased excretion of collagen in urine and plasma may be 
explained by a higher rate of tissue remodeling and turnover, as matrix metalloproteinases 
(MMPs) [159-161] are differently expressed in CRLM and CRC compared to healthy liver and colon 
tissue, respectively [275-277]. However, the upregulation in CRLM of proteins related to collagen 
production has not been shown. 
We aim to study the changes in collagen induced by CRLM with mass spectrometry in a well 
powered data set. We determined which specific collagen types are altered, if proteins in the 
collagen turnover pathway are altered, and if we can define a specific protein footprint of the 
primary tumor in the metastasis. 
RESULTS
PATIENT CHARACTERISTICS
Patients with CRLM had a median age 69.2 years (interquartile range [IQR] 60.5-74.7) and 
were mostly male (66.7%). Patients had a median of 1 (maximum 7) tumor, being moderately 
differentiated in 28 out of 30 patients. The CRLM tumor had a median size of 2.4 cm (IQR 1.4-3.5). 
The primary tumor was located in colon (47%), rectum (43%), and sigmoid (10%). Patients with 
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CRC had a median overall age of 71.1 years (IQR 54.8-80.9 years). The patients with liver fibrosis 
(FIB, ranging from moderate to severe fibrosis) had a median overall age of 59 years (IQR 58-59 
years) and were all male. These patients developed fibrosis due to a combination of different 
causes: viral hepatitis (3 out of 5), HCC (5 out of 5), steatosis (1 out of 5), steatohepatitis (2 out 
of 5). Additional information is found in the supporting information S-4.
DATA ASSESSMENT 
Normalization
Normalized values obtained from healthy adjacent liver tissue (control) and CRLM tissue did 
not differ significantly (P=0.58) 
Permutation
In the true data set of control vs. CRLM tissue, 5812 of the 20,635 peptides (28.1%) were 
tested significantly different. In the permutated data, an average of 631 (3%) peptides was 
significantly different. The true data set contained more significant peptides than the average 
of the permutation plus twice the SD (5812> > ~ 631; P< 0.05) of the permutated data.
PROTEOMICS
Top 10 proteins down- and upregulated
In total 2817 proteins were identified in CRLM and control tissue (see supporting information 
S-8). The 10 proteins with the highest absolute number of down- and upregulated peptides 
are shown in table 1. Many downregulated proteins were present in liver specific pathways 
(table 1). Furthermore, seven of the top 10 upregulated proteins in CRLM tissue originated 
from ECM.
Table 1. Top 10 proteins with the highest absolute number of peptides down- or upregulated in CRLM.
Protein Gene name  Fold changei # peptidesii
<0 >0
Downregulated
Carbamoyl-phosphate synthase [ammonia], mitochondrial CPS1 135 0 141
Fatty acid synthase FASN 87 0 91
Spectrin alpha chain, non-erythrocytic 1 SPTAN1 62 0 87
C-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 55 0 57
Glycogen debranching enzyme AGL 46 0 46
Cytosolic 10-formyltetrahydrofolate dehydrogenase ALDH1L1 44 0 48
Aldehyde oxidase AOX1 40 0 43
Pyruvate carboxylase, mitochondrial PC 40 1 46
3-ketoacyl-CoA thiolase, mitochondrial ACAA2 39 0 41
Alcohol dehydrogenase 4 ADH4 39 0 41
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Table 1 continued.
Protein Gene name  Fold changei # peptidesii
<0 >0
Upregulated
Collagen alpha-1(I) chain COL1A1 11 238 286
Collagen alpha-2(I) chain COL1A2 10 158 189
Collagen alpha-1(III) chain COL3A1 16 135 210
Fibrillin-1 FBN1 1 99 107
Filamin-A FLNA 3 90 105
Fibronectin FN1 1 77 85
Myosin-9 MYH9 2 66 125
Plectin PLEC 5 50 128
Collagen alpha-1(XII) chain COL12A1 2 50 58
Collagen alpha-2(V) chain COL5A1 1 49 50
i The number of peptides with a fold change > or < 0 and P<0.05. The fold change is based on 10log values. ii Number of 
identified peptides per protein. Gene names in bold are involved in liver processes (upper half, downregulated), gene 
names underlined are related to the ECM (lower half, upregulated).
Collagen in CRLM
We then analyzed the number of differentially expressed collagen peptides and collagen 
alpha chains. In CLRM tissue were 1137 collagen peptides identified, from which 819 peptides 
(72%) were up- and 55 peptides (4,9%) were downregulated. Overall, we observed an increased 
collagen level in CRLM vs. control tissue (P<0.0001, linear-fold change 1.67). Furthermore, 
19 of the 22 collagen alpha chains were significantly upregulated (table 2). COL12A1 was the 
most differentially expressed collagen alpha chain (2-fold change, 86% of identified peptides 
[n=50] significantly upregulated). An unsupervised clustering was performed based on all 
collagen peptides that separated both groups, except for four samples (CRLM-5, -9, -10, and 
-25) The four samples (CRLM-8, -12, -19, and -21) containing up to 50% control tissue were evenly 
clustered within the CRLM group (Figure 1). CRLM-10 had much lower mass spectrometry 
(MS) intensities for collagen peptides than the rest of the CRLM samples. However, in the 
normalization process this sample remained within the normal range of samples.
Table 2. Types of collagen identified and the number of peptides significantly up- and downregulated.
Collagen types # Peptidesi
Fold change
P-valueiii Fold changeiv
>0ii <0ii
P02452 COL01A1 286 239 11 1.84x10-09 1.7
P08123 COL01A2 189 158 10 9.4x10-10 1.7
P02458 COL02A1 5 1 0 2.4x10-03 1.2
P02461 COL03A1 210 135 16 7.6x10-06 1.5
P02462 COL04A1 33 24 3 7.0x10-07 1.5
P08572 COL04A2 33 30 0 2.92x10-12 2.0
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Table 2 continued.
Collagen types # Peptidesi
Fold change
P-valueiii Fold changeiv
>0ii <0ii
P53420 COL04A4v 1 1 0 5.19x10-06 1.9
P20908 COL05A1 31 30 0 3.15x10-14 2.0
P05997 COL05A2 50 49 1 7.73x10-16 2.3
P25940 COL05A3v 1 1 0 6.2x10-04 1.6
P12109 COL06A1 35 10 4 2.8x10-02 1.2
P12110 COL06A2 30 8 1 1.7x10-03 1.3
P12111 COL06A3 96 39 2 6.5x10-04 1.3
Q02388 COL07A1 2 2 0 9.7x10-11 2.2
P27658 COL08A1v 1 0 1 1.1x10-02 0.7
Q03692 COL10A1 7 6 0 2.3x10-08 1.7
P12107 COL11A1 5 4 0 3.5x10-14 2.0
Q99715 COL12A1 58 50 2 6.9x10-14 2.0
Q05707 COL14A1 46 29 3 8.8x10-07 1.5
P39059 COL15A1 2 2 0 7.1x10-08 1.8
Q07092 COL16A1 2 1 0 6.7x10-01 1.0
P39060 COL18A1 14 1 1 6.2x10-01 1.0
i The number of peptides identified per collagen alpha chain. ii The number of peptides with a fold change > or < 0 and 
P<0.05. The fold change is based on 10log values. iii Indicates the P-value at the protein level. iv Indicates the true fold 
change at the protein level (not the 10log value).
v These proteins are identified with one peptide and their identification is considered as less reliable compared to 
proteins identified with 2 or more peptides.
 
Figure 1. Unsupervised clustering at the patient level (horizontal) and collagen peptide level (vertical). 
The yellow and red regions at the top indicate control liver and CRLM tissue, respectively. The color 
scheme in the cluster analysis itself is from yellow-low to red-high.
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COLLAGEN TURNOVER RELATED PROTEINS
The observed upregulation of collagen in CRLM may be due to changes in the normal 
turnover of collagen in the liver. To test this hypothesis, 65 different proteins included in 
collagen turnover pathways were retrieved from the “Reactome Pathway Knowledgebase” [278, 
279]. Twenty-four of these 65 proteins were identified, 17 (~68%) of which were significantly 
upregulated in CRLM tissue. Sixteen of the 17 upregulated proteins are included in the 
collagen synthesis and/or fibril forming pathways (table 3). Supporting information S-5 
contains addition information.
Table 3. An overview of the identified proteins involved in collagen synthesis and degradation.
Biological role
Protein 
(Uniprot)
Protein name # Peptidesi
Fold changeii # Proteinsiii
>0 <0 P-value Fold change
B Q8NBJ5 COLGALT1iv 1 1 0 6.6E-05 1.78
B P14780 MMP9 4 2 0 1.8E-03 1.44
B Q32P28 P3H1 iv 1 0 0 1.7E-02 1.42
B P13674 P4HA1 7 3 1 1.9E-06 1.44
B Q15113 PCOLCE 4 4 0 4.6E-13 2.22
B Q15149 PLEC 128 50 5 4.7E-05 1.32
B Q02809 PLOD1 2 2 0 2.6E-11 2.17
B O00469 PLOD2 iv 1 1 0 6.6E-03 1.38
B O60568 PLOD3 5 3 0 2.8E-06 1.61
B,F P07237 P4HB 42 1 36 1.6E-18 0.48
B,F P50454 SERPINH1 13 11 0 7.4E-14 1.94
D P07339 CTSD 20 0 15 1.2E-05 0.65
D P08246 ELANE 6 3 0 1.7E-04 1.39
D P12955 PEPD 4 4 0 6.2E-08 0.59
D P23284 PPIB 14 0 11 9.4E-08 0.63
F P25774 CTSS 2 1 0 8.9E-02 1.23
F Q03001 DST iv 1 0 1 1.3E-06 0.50
F P23229 ITGA6 8 6 0 3.6E-07 1.61
F P16144 ITGB4 17 13 3 1.4E-09 1.60
F Q16787 LAMA3 3 3 0 7.4E-09 1.81
F Q13751 LAMB3 5 5 0 6.0E-11 1.93
F Q13753 LAMC2 2 1 0 3.2E-05 1.56
F Q8IUZ5 PHYKPL iv 1 0 1 4.9E-12 0.40
F,D P07858 CTSB 13 2 5 8.5E-02 0.88
The listed proteins are involved in three different pathways, annotated as: F, assembly of collagen fibrils and other 
multimetric structures; B, collagen biosynthesis and modifying enzymes; D, collagen degradation.
i Number of peptides identified per protein. ii Number of peptides that are significantly different and have a fold change 
> or <0. The fold-change is based on 10log values. iii P-values calculated over the summed ranked peptides followed by the 
fold change. The fold change shown is a true value (not a 10log value).
iv These proteins are identified with one peptide and their identification is considered as less reliable compared to 
proteins identified with 2 or more peptides.
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CRC PROTEIN SIGNATURE IN CRLM
Next, we studied the presence of a correlation between collagen levels in CRLM and CRC 
tissue. For COL10A1, COL12A1, COL14A1, and COL15A1, an absence or low number of unique 
peptides was observed in healthy colon and healthy liver tissue, but a higher number of 
unique peptides was present in CRC and CRLM tissues (supporting information S-6), being 
most apparent for COL12A1.
 
Furthermore, presence of proteins specific for colon tissue in CRLM and control tissues was 
studied. Elevated expression of 165 genes was found in colon tissue and in CRLM tissue 25 
corresponding proteins were identified (table 4). Supporting information S-7 contains 
additional information. Six proteins matched the set criteria and were considered unique for 
colon tissue vs. control liver tissue and were found significantly higher in CRLM tissue than 
control tissue.
IMMUNOHISTOCHEMISTRY 
MS data was cross-validated by IHC staining of COL12A1 in CRLM and control tissue. CRLM 
stroma tissue stained positive for COL12A1 (Figure 2a,b), except for three tissues (CRLM-19, 
-20, and -28, Figure 2c). Control tissue did not show positive staining (Figure 2d). The three 
negatively stained CRLM tissue sections did cluster with the rest of the CRLM samples by 
proteomics (Figure 1). Based on summed peptide ranking the COL12A1 values of the three 
negative IHC tissues were above 3*SD of the control, and 0, 9, and 18 peptides were respectively 
identified per sample, indicating that by proteomics these samples can be detected correctly.
The IHC staining of COL12A1 is present in the ECM. However, the staining was not equally 
distributed in the ECM of the CRLM tissue. Furthermore, studying tissue sections to determine 
IHC scoring revealed distortions in the CRLM morphology compared with the control tissue 
(Figure 2). In addition, CRC and healthy colon tissue (control C) were stained. CRC tissues 
showed, similar to CRLM, staining of the ECM for COL12A1. Staining was also observed in the 
nuclei of epithelial cells in healthy colon tissue by COL12A1 antibody NBP1-88062 (Figure 2g). 
The other COL12A1 antibody (HPA009143) did not show staining of the epithelial cells, but 
stained in addition to the collagen present in tumor stroma smooth muscle tissue (Figure 
2h). Fibrotic liver tissue (FIB) was stained by IHC for COL12A1 and no positive staining was 
observed (Figure 2f ).
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Table 4. Colon-specific proteins are upregulated in CRLM. 
Protein Genei
Fold changeii 
# peptidesiii
<0 >0
Villin 1 VIL1 1 18 26
Polymeric immunoglobulin receptor PIGR 2 12 19
Fatty acid binding protein 1 FABP1 17 0 17
Cadherin 17 CDH17 1 11 16
Keratin 20, type I KRT20 0 11 15
Carbonic anhydrase II CA2 11 0 12
Galectin-4 LGALS4 0 6 10
Carbonic anhydrase I CA1 7 1 8
UDP-glucuronosyltransferase 1-8 UGT1A8 7 0 8
Carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 0 5 7
IgGFc-binding protein FCGBP 1 3 7
Meprin A subunit alpha MEP1A 0 2 7
Glycoprotein A33 GPA33 0 5 6
UDP-glucuronosyltransferase 2B15 UGT2B15 5 0 6
Mucin 13 MUC13 0 5 5
Protein phosphatase 1 regulatory subunit 1B
PPP1R1B/
DARPP32 0 5 5
Epidermal growth factor receptor kinase substrate 8-like protein 3 EPS8L3 1 2 4
Protein FAM3D FAM3D 0 2 4
Carcinoembryonic antigen-related cell adhesion molecule 6 CEACAM6 0 3 3
Left-right determination factor 1 LEFTY1 1 1 3
Sulfotransferase family cytosolic 1B member 1 SULT1B1 2 0 3
Carcinoembryonic antigen-related cell adhesion molecule 1 CEACAM1 0 2 2
Carcinoembryonic antigen-related cell adhesion molecule 7 CEACAM7 0 2 2
Protein-arginine deiminase type-2 PADI2 0 1 2
UDP-glucuronosyltransferase 1-10 UGT1A10 2 0 2
These 25 proteins were identified with proteomics and, according to The Human Protein Atlas, are elevated in colon 
tissue compared with all other tissue types.
i Genes written in bold are considered unique for colon tissue. ii Number of peptides that are significantly different 
(p<0.05) and have a fold change > or <0. The fold change is based on 10log values. iii Total number of peptides identified 
for this protein.
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Figure 2. IHC staining of COL12A1. a) CRLM-1, IHC score 2; b) CRLM-8, IHC score 1.5; c) CRLM-20, IHC 
score 0; d) Control-8, IHC score 0; e) IHC scores for COL12A1 in control and CRLM tissue: 0, no staining; 
0.5, small focal staining; 1, focal staining; 1.5, few focal staining areas; 2, several focal staining areas; 2.5, 
staining more than 40% and less than 50%; 3, >50% staining; f ) FIB-1, IHC score 0; g) Control C-1, antibody 
NBP1-88062; h) Control C-1, antibody HPA009143, healthy tissue; i) CRC-5, IHC score: 1. 
DISCUSSION
In this study we focused on the presence of collagen in CRLM and we showed by using 
proteomics that we could distinguish all 30 CRLM samples correctly from normal liver tissue 
in a relative detailed protein level. Twenty-two of the 44 known collagen alpha chains were 
observed in CRLM and/or control tissue (healthy adjacent liver tissue). The remaining 22 
chains were not identified, possibly due to low concentration or absence in the liver. 
Previously, Naba et al., showed the presence of specific collagen alpha chains in colon, CRC, 
liver, and CRLM tissue in a small sample set (n=3) including a pooled control (n=2) [152]. Naba 
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et al. observed more collagen types, although they performed additional enrichment and 
extensive fractionation. The authors indicated that validation needs to be performed in a larger 
sample set, which was confirmed by our power calculation with an estimation of (minimum) 
25 samples per group. In the present study we analyzed from 30 individuals matched control 
and CRLM tissue providing a well-powered data set. An upregulation of collagen peptides 
(P<0.0001) in CRLM tissue compared to control tissue was observed as well as upregulation 
of individual collagen alpha-chains. Three collagen alpha chains (COL8A1, COL16A1, COL18A1) 
were not significantly affected. COL18A1 is mainly involved in the development of the eye [280], 
central nervous system, and liver structures [281, 282]. Musso et al. demonstrated that COL18A1 
production is not increased in CRLM in comparison with liver tissue, and therefore may be 
considered as a negative control [283]. The low number (two or less) of identified peptides for 
COL4A4, COL5A3, COL7A1, COL8A1, COL15A1, and COL16A1 indicate relative low levels in CRLM.
The increase in collagen is accompanied by an increase in proteins related to collagen 
synthesis, of which several have been described separately to stimulate tumor proliferation: 
P4HA1[284, 285], PCOLCE [285], PLOD1[285], PLOD2 [286], PLOD3[285], and SERPINH1 [287]. The number 
of proteins identified from the collagen degradation pathway were not sufficient to draw a 
conclusion regarding down- or upregulation. Only one collagenase was identified, MMP-9 
(fold change 1.44). MMP-9 cleaves collagen types IV, V, XI, and XIV [159-161]. Other MMPs might 
also be upregulated [275, 276], although they were not identified. 
COL12A1 MS data was cross-validated with IHC and both techniques showed significant 
upregulation of COL12A1. During scoring of the tissues, no abnormalities were observed in 
healthy adjacent liver tissue. Nevertheless, the presence of molecular abnormalities cannot 
be ruled out with certainty. We tried to exclude direct tumor effects by taking control tissue 
which was at least at a distance of 1 cm away from the tumor. Many articles referring to 
pre-metastatic niches (PMN) were published [288-291]. A PMN is formed by interaction of the 
potential metastasis site with proteins excreted from the primary tumor, creating a niche 
that is favorable for the growth of a metastasis. We were not able to visualize COL12A1 in three 
CRLM tissue sections with IHC, although increased COL12A1 levels were detected with MS. In 
CRC, COL12A1 was mainly present in stroma, analogous to CRLM. 
However, in colon tissue it was surprisingly observed inside the nuclei of epithelial cells, with 
repetitive staining. We could not validate the staining of the nuclei of the epithelial cells 
with another antibody (HPA009143). This indicates that staining of the nuclei is most likely 
false positive. This antibody (HPA009143) which stains COL12A1 also showed cross-reactivity. 
In this case smooth muscle tissue, stained false positively. Both antibodies showed exactly 
the same staining for collagen structures and showed both additional cross-reactivity (nuclei 
endothelial cell and smooth muscle tissue). 
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The shotgun proteomics data allowed us to search for specific proteins produced by CRLM, 
which originate from the primary colon tumor tissue. First, we looked into collagen 
types that were expressed higher in CRC with respect to colon tissue, and were also more 
abundant in CRLM with respect to liver tissue. Four collagen types matched these criteria: 
COL10A1, COL12A1, COL14A1, and COL15A1, and the abundance was strongest for COL12A1. We 
hypothesize that these four collagen types visible in CRLM are a sign of origin of the primary 
tumor and highly specific for CRLM. We cannot exclude the possibility that fibrotic tissue is 
triggered by the metastatic cells to produce e.g. COL12A1, however we observed in five fibrotic 
tissue sections that COL12A1is not present in just fibrotic tissue itself. Collagen type X [292] and 
type XII [248] are described to be upregulated in CRC, however collagen type XIV and XV are not 
described. In CRLM collagen type X, XII, XIV, and XV are not described in relation with CRLM 
in literature.
 
Colon-specific proteins were selected from the Protein Atlas, after applying the selection 
criteria six proteins remained. These remaining proteins (CDH17, KRT20, CEACAM5, GPA33, 
MUC13, and PPP1R1B/DARPP-32) are colon specific and were significantly present in the CRLM 
tissue. Previous reports state that KRT20 [293], MUC13 [152, 294], CEACAM5 [295], and GPA33 [296, 297] 
are differently expressed in CRLM tissue; while, CDH17 and PPP1R1B/DARP-32 have not been 
described previously. It is likely that CDH17 is involved in cell organization and stimulates 
tumor proliferation; [298] while, PPP1R1B/DARPP-32 is highly expressed in CRC tissue and is a 
predictor for metastasis [299]. Furthermore, six of the 10 top downregulated proteins are related 
to liver-specific processes. The relative loss of proteins involved in liver processes in the 
tumor relates to a known decrease of hepatocytes in tumor tissue [300]. The top 10 upregulated 
proteins included collagen and two other ECM proteins, fibrillin-1 (FBN1) and fibronectin 
(FN1), suggesting the ECM composition strongly deviates from normal.
  
We conclude that collagen is upregulated in CRLM compared to control tissue and that 
specific collagen types (COL10A1, COL12A1, COL14A1, and COL15A1) from the primary tumor 
can be detected in the CRLM tissue as well. The collagen changes found in CRC and CRLM may 
reflect changes of the ECM related to tumor proliferation and seeding into the liver. These 
data may help to define new biomarkers to be used in CRLM detection after treatment of the 
primary tumor or its metastases. 
EXPERIMENTAL PROCEDURES
EXPERIMENTAL DESIGN AND STATISTICAL RATIONALE
This study was approved by the Erasmus MC review board (MEC-2007-088) and we have 
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worked according to the Declaration of Helsinki. We identified collagen types which are 
differently present in paired (n=30) CRLM tissue compared to normal adjacent liver tissue 
(control). Presence of colon or CRC specific proteins in CRLM was studied by comparing 
CRLM, control, healthy adjacent colon (n=5), and CRC tissue (n=5). Fibrotic tissue (n=5) 
was analyzed to determine if COL12A1 upregulation is a general liver process or caused by 
metastatic cells. CRLM, control liver, CRC, and colon tissue were analyzed by IHC (COL12A1 
antibody: NBP1-88062) and mass spectrometry. Fibrotic liver (FIB) tissue was analyzed by IHC 
(COL12A1 antibody: NBP1-88062). Colon tissue was additionally stained with a second COL12A1 
antibody (HPA009143) to verify the unexpected staining of epithelial nuclei.
Sample size of the CRLM and control tissue were based on a power analysis (alpha=0.05, 
beta=0.20). Mean and standard deviation (SD) used for the power analysis were calculated 
on the overall data of log-transformed significant upregulated collagen peptides in CRLM 
and control tissue of five patients (control mean=5.00, CRLM mean=5.94, pooled SD=1.18). 
The power analysis depicted a sample size larger than 25 samples per group to determine the 
observed differences in the subset. No replicate measurements were performed, we assumed 
the biological variation to be much larger than the technical variation as has also been 
described in literature for the technique used [263].
Quality of the LC-MS/MS runs was monitored by measuring samples first on a test system to 
identify incomplete digestions and determine the presence of other components influencing 
the chromatography. Furthermore, after every 10 samples an QC sample was measured 
containing a set of peptides spread over the whole gradient to monitor possible retention 
time shifts or loss of intensity in the mass spectrometer. The peptides showed a retention 
time variation which remained within 0.2 min.
Data was assessed by analysis of the normalization by a t-test and background was assessed 
by permutation testing, see paragraph Data assessment (Experimental section). Proteins 
included in collagen turnover pathways were analyzed. Statistics are described in the 
paragraphs Data Analysis and in Statistical Analysis ( Experimental section).
Mass spectrometry data was orthogonal cross-validated by IHC on the most distinctive 
collagen type.
SAMPE SELECTION CRITERIA
All samples were provided by the department of Pathology, Erasmus MC, and examined (by a 
GI-pathologist) for the presence of healthy and tumor tissue in the same section. Four CRLM 
sections were included that contained up to 50% control tissue (CRLM-8, -12, -19, and -21), the 
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other sections were free of control tissue. Control liver sections were demonstrated to be free 
of tumor tissue by standard histological examination and were taken at a minimum distance 
of 1 cm away from the tumor. All CRC sections included contained non-tumorous colon tissue 
(by standard histological examination). All samples were included in the data analysis. Tissue 
sections and patient information were handled according to the “Human Tissue and Medical 
Research: Code of Conduct for Responsible Use (Federa, 2011)”. Therefore, no approval of the 
Medical Research and Ethics Committee was required.
CHEMICALS
Ultra-high pressure liquid chromatography grade nano-LC solvents were obtained from 
Biosolve (Valkenswaard, the Netherlands). Two COL12A1 antibodies (NBP1-88062 and 
HPA009143) were obtained from Bio-Connect BV (Huissen, the Netherlands). EnVision 
Detection Systems Peroxidase/DAB, Rabbit/Mouse was obtained from Dako (Heverlee, 
Belgium). TRIS-EDTA for Heat-Induced Antigen Retrieval (HIAR) was obtained from Klinipath 
(Duiven, the Netherlands). Other chemicals were obtained from Sigma-Aldrich (Zwijndrecht, 
the Netherlands).
IMMUNOHISTOCHEMISTRY STAINING (IHC)
Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections were analyzed by MS and IHC. 
Consecutive tissue sections (6 µm thickness) were cut. For IHC, tissue sections were 
deparaffinized and rehydrated, followed by inhibition of endogenous peroxidases. Prior to 
primary antibody labelling, HIAR was used. Samples were labelled with a primary antibody 
against COL12A1, followed by secondary labelling, visualized by incubation with DAB, and 
counterstained with hematoxylin. Tissue sections were scored by a GI-pathologist (MD). 
Tissues was scored according to the following criteria: 0, no staining; 0.5, small focal staining; 
1, focal staining; 1.5, few focal staining areas; 2, several focal staining areas; 2.5, staining 
more than 40% and less than 50%; 3, >50% staining; The full IHC protocol is available in the 
supporting information S-1.
SAMPLE TREATMENT FOR MASS SPECTROMETRY (MS)
Tissue sections for MS analysis were placed in an Eppendorf cup, per sample one tissue 
section was analyzed, irrespective from the size of the resection material. Injection volumes 
were normalized based on the UV-absorbance measured on a test system. The tissue sections 
were deparaffinized and rehydrated, followed by removal of formalin cross-links. Formalin 
cross-links were removed by incubation with a solution of Tris and Rapigest [301]. Followed by 
reduction, alkylation, and overnight trypsin digestion. Trypsin cleaves exclusively C-terminal 
to lysine or arginine unless proline is located at the C-terminal side [302]. The full protocol for 
sample treatment for MS analysis, and nano-LC and MS settings are available in the supporting 
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information S-1. Mass spectrometry data was made publicly accessible via the PRIDE archive, 
accession number: PXD008383. 
DATA ANALYSIS
MGF peaklist files were extracted from raw files by ProteoWizard (v3.0.9166). MGF were searched 
using the Mascot search engine (v2.3.2, Matrix Science Inc., London, UK) and the UniProt/Swiss-
prot database (20194 entries), as described by Singh et al. [303]. In short, the database search 
contained a mass tolerance of 10 ppm for the peptide mass, and 0.5 Da for the fragment mass. 
A maximum of 4 miss cleavages was allowed. Hydroxylation (+16 Da) of proline, lysine, and 
methionine were included as variable modifications and carbamidomethylation (+57 Da) of 
cysteine as fixed modification. Mascot search results were further analyzed by Scaffold (v4.6.2, 
Portland, OR, USA). In Scaffold protein confidence levels were set to a 1% false discovery rate 
(FDR), at least 1 peptide per protein, and a 1% FDR at the peptide level. FDRs were estimated 
by inclusion of a decoy database search generated by Mascot. Subsequently, the Scaffold data 
were imported into Progenesis QI (v4, Nonlinear Dynamics, Newcastle-upon-Tyne, United 
Kingdom) to align the LC runs. Features not matching the selection criteria: charge between 
2 and 5, and at least two isotopes were excluded from further analysis. Identifications from 
Scaffold were imported via Scaffold into Progenesis QI, followed by exporting the normalized 
abundance to Excel 2010 (Microsoft, Redmon, WA, USA). Duplicate feature intensities were 
summed. Data was further processed with Excel, GraphPad Prism (v5.01, La Jolla, CA, USA), 
and R (v3.3.1, Vienna, Austria). Prior to 10log-transformation, a relative small value of “10” was 
added, this to include missing values for further data analysis. The 10log-transformed data 
was used for statistics, thereby the data was assumed to be normally distributed after log-
transformation. Protein significance was determined by ranked peptide values, summation 
of all peptides per protein, and followed by an unequal variance t-test. In all following 
comparisons, an unequal variance t-test was used unless stated otherwise. P-values <0.05 were 
considered significant unless stated otherwise.
DATA ASSESSMENT 
CRLM and control MS data were assessed, this included the analysis of normalization for 
injection volumes, permutation testing, and intra- and intercollagen alpha chain correlations. 
To exclude a bias a priori in the data, normalization was tested by summation of all individual 
peptide values per patient, followed by testing for significance between CRLM and control 
tissue.
To exclude the possibility that results were found by chance in large datasets, permutation 
testing (n=1000 iterations) was performed using R. The R-script has been added to the 
supporting information S-2. Briefly, the data was randomly divided into two groups at the 
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peptide level; significant differences between the two groups were determined using the 
Wilcoxon signed-rank test. Significant P-values were summed per permutation and the 10log 
was taken. It was assumed that the distribution of the 10log summed significant P-values 
was normally distributed. If the true dataset value was greater than the average value of the 
permutation test plus twice the SD (p<0.05) , then a significant difference was assumed.
STATISTICAL ANALYSIS
An unsupervised cluster analysis was performed with R on ranked peptides. The R-code is 
available in the supporting information S-3. 
The observed upregulation of collagen can be due to a disturbance in its normal turnover. To 
test this hypothesis, proteins included into collagen turnover pathways were retrieved from 
the “Reactome Pathway Knowledgebase” [278, 279]. Three pathways present in the “Reactome 
Pathway Knowledgebase” are related to collagen production and degradation: “Collagen 
biosynthesis and modifying enzymes”, “Assembly of collagen fibrils and other multimetric 
structures”, and “Collagen degradation”. Although not included in the “Reactome Pathway 
Knowledgebase”, Xaa-Pro dipeptidase (PEPD) is involved in collagen degradation. PEPD 
cleaves Xaa-Pro and Xaa-Hyp, but not Pro-Pro, and is essential for the final degradation of 
collagen.
 PEPD was added to the retrieved list of proteins from the “Reactome Pathway Knowledgebase”.
The CRC protein signature in CRLM was determined at two levels: collagen specific and 
the general proteome. At the collagen level, the total unique peptide count was used as a 
measure of abundance. Proteins were considered as “hitchhiked” from the colon to CRLM 
if they matched the following criteria: 1) were marked in the Human Protein Atlas (www.
proteinatlas.org) as tissue enriched, group enriched, or tissue enhanced in colon tissue; 2) 
had an intensity based absolute quantification (iBAQ) value at the protein level for colon 
tissue but not for liver tissue; 3) the RNA expression level was 100-fold lower in the liver vs. 
colon tissue, and had five peptides or more identified per protein. iBAQ and RNA expression 
levels were taken from https://www.proteomicsdb.org/. 
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CHAPTER 6
Identification of 
4-hydroxyproline at the 
Xaa position in collagen 
by mass spectrometry 
ABSTRACT
Collagen has a triple helix form, structured by a [-Gly-Xaa-Yaa-] repetition, where Xaa and 
Yaa are amino acids. This repeating unit can be post-translationally modified by enzymes, 
where proline is often hydroxylated into hydroxyproline (Hyp). Two Hyp isomers occur 
in collagen: 4-hydroxyproline (4Hyp, Gly-Xaa-Pro, substrate for 4-prolyl hydroxylase) and 
3-hydroxyproline (3Hyp, Gly-Pro-4Hyp, substrate for 3-prolyl hydroxylase). If 4Hyp is lacking 
at the Yaa position, then Pro at the Xaa position should remain unmodified. Nevertheless, 
in literature 41 positions have been described where Hyp occurs at the Xaa position (?xHyp) 
lacking an adjacent 4Hyp. We report four additional positions in liver and colorectal liver 
metastasis tissue (CRLM). We studied the sequence commonalities between the 45 known 
positions of ?xHyp. Alanine and glutamine were frequently present adjacent to ?xHyp. We 
showed that proline, position 584 in COL1A2, had a lower rate of modification in CRLM than 
in healthy liver.
The isomeric identity of ?xHyp, i.e. 3- and/or 4Hyp, remains unknown. We present a proof 
of principle identification of ?xHyp. This identification is based on liquid chromatography 
retention time differences and mass spectrometry using ETD-HCD fragmentation, 
complemented by ab initio calculations. Both techniques identify ?xHyp at position 584 in 
COL1A2 as 4-hydroxyproline (4xHyp). 
 
Reprinted with permission from Journal of Proteome Research. 2019 May 3;18(5):2045-2051. 
Copyright 2019 American Chemical Society.
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INTRODUCTION
 
Collagen is a family of proteins well-known to be naturally present as a triple helix. The triple 
helix is structured by a [-Gly-Xaa-Yaa-]n repeating unit, where Xaa and Yaa can be different 
amino acids. This repeating unit can be post-translationally modified, the most common 
modification being the enzymatic hydroxylation of proline into hydroxyproline (Hyp). Two 
Hyp isomers have been observed, namely 4-hydroxyproline (4Hyp) and 3-hydroxyproline 
(3Hyp). 4Hyp is formed by 4-prolyl hydroxylase, which requires Gly-Xaa-Pro as substrate [304]. 
3Hyp is formed by 3-prolyl hydroxylase, which requires Gly-Pro-4Hyp as substrate.[305] 3Hyp 
and 4Hyp are involved in triple helix stability and fiber formation; the exact functional 
differences of 3Hyp and 4Hyp are not yet fully understood.[306-308]
In the literature, 45 positions have been reported where Hyp is present at the Xaa position 
[69-71, 73, 320]. However, these substrate positions do not match with known enzyme activity. 
Therefore, the identity of the enzyme generating Hyp at the Xaa position remains unknown. 
Hyp occurring at the Xaa position will be referred to as ?xHyp, where the “?” indicates the 
third or fourth position of the hydroxyl group positioned on proline, and the “x” to the Xaa 
position in the repeating unit observed in collagen (Gly-Xaa-Yaa). 40 out of the 41 positions 
have been identified by collagen PTM mapping with mass spectrometry, (in brackets the 
adjacent amino acid at the Yaa position is annotated): in COL4A1 of Murine Engelbreth-
Holm-Swarm position: 481 (Gln) [71]; in COL4A1 of Human lens capsule positions: 71 (Gln), 514 
(Gln), and 662 (Gln) [71]; in COL2A1 of Bovine positions: 214 (Ala), 220 (Gln), 358 (Val), 502 (Ala), 
646 (Ala), 696 (Ala), 796 (Ala), and 1099 (Ala) [70]; in COL5A1 of Bovine placenta: positions 509 
(Val), and 587 (Ala) [320]. In COL1A1 of human breast cancer 32 positions were identified, at the 
Yaa position were present: 2 times Gln, 3 times Arg, 10 times Ala, 1 time Gly, 1 time Pro, 2 times 
Val, 1 time Thr, 1 time Asp, 2 times Ile, and 2 times Ser.[73] Lysine was present 7 times at the Yaa 
position, however hydroxylysine was not included in the database search and therefore this 
finding is likely to be an artefact and is excluded from further analysis. The 41thposition has 
been identified in a specific peptide of COL1A2 in Bovine gelatin (position 812 (Ala)) which is 
part of a panel of collagen peptides to distinguish different animal sources of gelatin [69]. In 
addition to these 41 known positions, we report here four additional positions. We studied 
the sequence commonalities between these 45positions to identify a possible substrate for 
the unknown enzyme which modifies Pro into ?xHyp.
Kassel et al. distinguished 3Hyp and 4Hyp based on w-ions in mussel adhesive proteins 
by mass spectrometry (MS) [74]. Their method applied to our case did not result in isomer 
identification due to interference of the expected transitions of interest. We therefore 
developed a new MS-based method to distinguish 3Hyp and 4Hyp in collagen peptides. As a 
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proof of principle, we here show the identification of ?xHyp in one of the newly identified 
positions (GLHGEFGLP(4Hyp)GP(?xHyp)AGPR) based on both liquid chromatography 
retention time difference and MS experiments (electron transfer dissociation (ETD), followed 
by high-energy collision induced (HCD) fragmentations). By integration of experiments and 
ab initio calculations, we derive fragmentation pathways which rationalize our observations. 
We further validated both the liquid chromatography and the mass spectrometry method by 
analysis of synthetic peptides. In addition, we investigated if ?xHyp is differently present in 
metastatic tumors of colon rectal carcinoma.
MATERIALS AND METHODS
DATA COLLECTION
By re-analysis of bottom-up proteomics data uploaded at the PRIDE Archive (PXD008383), 
we were able to identify four new locations, based on MS2 fragmentation, of ?xHyp. The 
mass spectrometric data retrieved from the PRIDE Archive (PXD008383) was obtained from 
formalin-fixed, paraffin-embedded healthy liver tissue. Sample processing is described 
by van Huizen et al[26]. Two healthy liver tissue samples and corresponding colorectal liver 
metastasis (CRLM) tissue (control-6, control-18, CRLM-6, and CRLM-18) were used for further 
identification of ?xHyp.
 
The publication by van Huizen et al.[26] showed a strong upregulation of COL1A2 in CRLM 
compared to liver tissue (p= 9.4*10-10, fold change = 1.7). Based on their data we analyze in this 
manuscript if the ratio between COL1A2 containing the ?xHyp modification at location 584 
and COL1A2 lacking the ?xHyp modification is different between CRLM (n=30 samples) and 
healthy adjacent liver tissue (n=30 samples). Therefore, we analyzed the 10log-transformed 
data (the data is available in the supplemental information, S-1) for the ratio between the 
peptide containing ?xHyp GLHGEFGLP(4Hyp)GP(?xHyp)AGPR and peptide lacking ?xHyp 
GLHGEFGLP(4Hyp)GP(Pro)AGPR. In one liver sample (control-17), and in three CRLM samples 
(CLRM-4, CRLM-8, CRLM-14) the peptide containing ?xHyp could not be properly assigned 
and these data were therefore removed from data analysis. The overall COL1A2 levels of these 
four samples do not deviate from the other samples. Ratios are reported as an averaged ratio 
± standard deviation. The difference between the ratios was tested for significance by use 
of a t-test (with assumption of unequal variance). A p-value below 0.05 was considered as 
significant. 
MATERIALS
Synthetic peptides were ordered at Pepscan (Lelystad, the Netherlands) whereby the proline 
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at the Xaa position was modified: GLHGEFGLP(4Hyp)GP(Pro)AGPR, GLHGEFGLP(4Hyp)
GP(3Hyp)AGPR, GLHGEFGLP(4Hyp)GP(4Hyp)AGPR. These synthetic peptides will be 
abbreviated below as GLH-Pro, GLH-3Hyp, GLH-4Hyp, respectively.
MASS SPECTROMETRIC ANALYSIS ON SYNTHETIC PEPTIDES BY DIRECT INFUSION
By direct infusion of the three synthetic peptides into an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Fischer Scientific, San Jose, CA, USA), we set-up an ETD-HCD method 
to distinguish the three synthetic peptides; ETD is in MS2 mode and subsequent HCD 
in MS3 mode. Synthetic peptides were infused at a concentration of 0.02 mM in a 50:50 
water:methanol, and 0.1% formic acid solution at a speed of 4 µL/min. Direct infusion was 
performed using an ESI-source with a spray voltage of 3.7 kV in the positive ion mode and 
kept at a temperature of 275 oC. Both doubly and triply charged ions were observed, of which 
the triply charged ions were selected for further ETD fragmentation. Triple charged ions were 
collected for 118 ms or until the AGC target of 5.0e4 was reached. Fluoranthene was used as an 
ETD reagent and was collected for 200 ms or until the AGC target of 2.0e5 was reached. Optimal 
reaction time between fluoranthene and triply charged peptide ions of interest was 200 ms. 
After ETD fragmentation of the triply charged ions at m/z 793.25 for GLH-Pro and m/z 798.58 
for GLH-3Hyp and GLH-4Hyp, we observed charge-reduced radical cations, [M+3H]2+•. These 
charge-reduced peptide ions were further fragmented by HCD collision. HCD fragmentation 
was performed on the charge-reduced fragment ions with m/z 739.8 for GLH-Pro and m/z 
498.58 for GLH-3Hyp and GLH-4Hyp. HCD collision energy was set to 35 %. ETD-HCD fragments 
were collected for 500 ms or until the AGC target of 5.0e5 was reached, followed by detection 
in the Orbitrap mass analyzer set at 120,000 resolution. The spectra shown in figure 5 have 
been averaged over 4 min.
AB INITIO CALCULATIONS
Ab initio calculations were performed to validate the ETD/HCD fragmentation. In the ab initio 
calculations, we used a model version of the peptides (as shown in figure 4) whereby the 
charged C- and N-termini were blocked with NH-CH3 and (C=O)-CH3, respectively. All model 
molecules were built using GaussView 6 and optimized with Gaussian 16 at the MP2 level of 
theory with the 6-31g(d,p) basis set [321]. For the open-shell stable species investigated here, the 
unprotected <S2> values were within 0.7501-0.7504 indicating negligible spin contamination. 
All presented molecular structures are fully optimized and minima are confirmed through 
the vibrational frequency analysis. Vibrational frequency calculations also provide zero-
point energy correction (ZPE) which is applied to the energy displayed.
IDENTIFICATION BY NANOLC-ESI-ETD-HCD OF ?XHYP 
Synthetic peptides were diluted to a concentration of 2 nM and mixed in a 1:1 ratio with 
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the liver tissue digest. The following mixtures were analyzed: the digest with 0.1% TFA, with 
GLH-Pro, with GLH-Pro + GLH-3Hyp, and with GLH-Pro + GLH-4Hyp. This was performed 
for control-6, control-18, CRLM-6, and CRLM-18 [26]. The same nanoLC method was used as 
described by van Huizen et al. [26], the only difference being that a 30 min gradient instead of 
a 90 min gradient was used. The nanoLC was coupled to a nanospray source of an Orbitrap 
Fusion. The above mentioned ETD-HCD mass spectrometry method was used for detection. 
To increase the number of MS3 scans on a LC time scale, ions were analyzed in the ion trap of 
the Orbitrap Fusion. LC-MS/MS/MS runs were made publicly accessible via the PRIDE archive, 
accession number: PXD011784.
SEQUENCE LOGO
Sequence commonalities were studied by generating a sequence logo for the 41locations 
reported in literature [69-71, 73, 320] and the four additional locations reported in this study. 
Montgomery et al. reported the lysine to be present at the Yaa position next to ?xHyp.[73] We 
rejected the presence of ?xHyp next to lysine, hydroxylysine was not included in the database 
search and is therefore likely to be an artefact.[73] In total, 45 positions were taken into account 
for the sequence logo. The sequence of nine amino acids in front and after ?xHyp were 
selected for the generation of a sequence logo. ?xHyp was set to position “0” in the sequence 
logo. Hydroxylation of proline at other locations were not considered. The Sequence Logo 
was generated via an online tool (http://weblogo.berkeley.edu/logo.cgi).
RESULTS
REANALYSIS OF PRIDE DATABASE DATA
New Hyp at Xaa locations
Re-analysis of bottom-up data of liver tissue (PXD008383) resulted in the identification of 
four peptides containing ?xHyp, namely COL1A1: GP(?xHyp, pos. 417)SGPQGPGGPP(4Hyp)
GPK; COL1A1: GPSGPQGP(?xHyp, pos. 423)GGPP(4Hyp)GPK; COL1A2: GLHGEFGLP(4Hyp)
GP(?xHyp, pos. 584)AGPR; and COL1A2: GEAGAAGP(?xHyp, pos. 701)AGPAGPR. Peptides 
lacking the aberrant hydroxylation were also detected.
Sequence logo
The identity of the enzyme modifying Pro into ?xHyp is unknown. To get more insight into 
this unknown enzyme, we search for sequence commonalities by generating a sequence logo. 
The generated sequence logo (figure 1) was based on 41 ?xHyp locations reported in literature 
[69-71, 73, 320] and the additional four locations reported in this manuscript. Glycine is 
dominantly present at every third position due to the repeating unit. At the Yaa position 
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adjacent to ?xHyp (position 1), alanine (47%), or glutamine (16%) is frequently present. 
Glutamine is mainly observed in collagen type IV. Four out of four ?xHyp positions reported 
in collagen type IV contained glutamine at the Yaa (position 1). The repeating units adjacent 
to ?xHyp frequently contain alanine and proline.
Figure 1. Sequence logo based on 16 ?xHyp locations described in literature [69-71, 320] and the additional 
4 reported in this manuscript. ?xHyp was set at position “0”.
?xHyp in colorectal liver metastasis
We used proteomics data of colorectal liver metastasis (n=30) and healthy adjacent liver 
tissue (n=30) as described[26] to calculate the ratio between the peptide containing ?xHyp and 
the peptide lacking ?xHyp. It was found in that the ratio in liver tissue was 0.54 ± 0.11 while 
the ratio in CRLM was 0.31 ± 0.07 (figure 2). Thus the ratio in healthy adjacent liver tissue is 
significant different from CRLM tissue (p-value = 1*10-9). The decreased ratio in CRLM is caused 
by a strong significant increase of the peptide lacking ?xHyp from 6.8 ± 0.3 in liver to 7.4 ± 0.4 
in CRLM (p-value = 2*10-8), while the peptide containing ?xHyp increased significantly but 
only slightly from 6.5 ± 0.3 in liver to 6.8 ± 0.4 in CRLM (p-value = 9*10-4). 
Figure 2. The ratio between the modified and unmodified peptides (GLHGEFGLP(4Hyp)GP(Pro)AGPR 
and GLHGEFGLP(4Hyp)GP(?xHyp)AGPR, respectively) 
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In figure 2 two liver samples have a higher ratio (Control-16, Control-19) than the others and 
in the CRLM one sample (CRLM-24) has a deviating ratio. These three samples do not have 
deviating COL1A2 levels.
MASS SPECTROMETRY ANALYSIS ON SYNTHETIC PEPTIDES BY DIRECT INFUSION
Partial mass spectra, acquired by ETD-HCD (MS3) fragmentation for GLH-Pro, GLH-3Hyp, and 
GLH-4Hyp are shown in figure 3. Comparison of these ETD-HCD fragmentation mass spectra 
of GLH-3Hyp and GLH-4Hyp reveals that the m/z 400 signal is more intense for GLH-3Hyp.The 
m/z 454 signal is not observed for GLH-3Hyp, but is present for GLH-4Hyp. While the peak at 
m/z 400 corresponds to the y4 fragment ion (AGPR+), the peak at m/z 454 does not match any 
a-, b-, c-, x-, y-, or z-ions. 
Figure 3. Zoom-in of the ETD-HCD mass spectra of the synthetic peptides acquired by direct infusion. 
GLH-3Hyp and GLH-4Hyp are distinguishable by singly charged fragments at m/z 400 and 454.
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We propose a fragmentation pathway (figure 4) for GLH-3Hyp and GLH-4Hyp which explains 
the difference observed between GLH-3Hyp and GLH-4Hyp fragmentations in the synthetic 
peptides. Electron transfer dissociation (ETD) of the triply charged ions results in the 
neutralization of the proline moiety, whereby a hypervalent nitrogen species is formed 
which undergoes immediate ring opening [322] leading to a carbon-centered radical. The latter 
species does not dissociate further under ETD conditions. The doubly-charged ring-opened 
structure generated by ETD is subsequently activated by high energy dissociation (HCD). The 
activation of the ring-opened structure results in -cleavage at the carbon-centered radical, as 
shown in figure 4. This process produces telltale fragment ions detected at m/z 470 for GLH-
3Hyp and at m/z 454 for GLH-4Hyp. Fragment ions at m/z 454 are indeed observed in the MS3 
spectra of the GLH-4Hyp peptide ions, but the m/z 470 ions are not detected in the GLH-3Hyp 
peptide ions. Also, we do not observe the complementary fragments at m/z 1024 and 1040 
for GLH-3Hyp and GLH-4Hyp, respectively. The high mass part of the mass spectrum mainly 
shows intense C- and Z-ions. 
To get further mechanistic insight on the collision-induced dissociation of the ETD generated 
radical ions, we calculated at the ab initio level of theory the reaction enthalpies for these 
dissociation processes. We used model molecules presenting the carbon-centered radical 
proline ring, respectively 3Hyp an 4Hyp in figure 4 with R1 and R2 being methyl groups. The 
relative energies for the HCD fragmentations are shown below the structures, see figure 4. 
The initial fragmentation of the collisional activated model 3Hyp radicals requires 88 kJ/
mol starting from the ring-opened structure, whereas the same fragmentation for the model 
4Hyp radicals is 138 kJ/mol endothermic. Thus, m/z 470 ions are expected to be detected in 
the ETD/HCD mass spectrum of the GLH-3Hyp ions since the corresponding ions, generated 
by a more energy demanding process, are clearly detected at m/z 454 in the ETD/HCD mass 
spectrum of the GLH-4Hyp ions. 
However, our ab initio calculations indicate that the m/z 470 ions can consecutively undergo 
a rearrangement initiated by a 1,5-hydrogen shift to eliminate 3-oxoprop-2-enal to produce 
m/z 400 ions as observed in the MS3 spectrum in figure 3. This secondary process only requires 
146 kJ/mol and is thus expected to occur. Such a process is not expected to occur for the GLH-
4Hyp ions. When comparing the three mass spectra of figure 3, the higher intensity of the m/z 
400 signal in the specific case of the GLH-3Hyp peptide may be ascribed to the presence of the 
consecutive m/z 470 to m/z 400 decomposition. 
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Figure 4. Proposed ETD-HCD fragmentation pathway. R1 = [GLHGEFGLP(4Hyp)G + H]
+ , R2 = [AGPR + 
H]+ with corresponding m/z values shown below the structures which refer to figure 3. For the model 
compound used for ab initio calculations R1 = R2 = CH3. Energy levels calculated by our ab initio method 
are shown below the corresponding structures. Heat of formation of the HCD fragments are calculated 
relative to the third structure, where the proline backbone has been broken by ETD to yield a carbon-
centered radical. 
?XHYP IDENTIFICATION BY NANOLC-ESI-ETD-HCD
Identification of ?xHyp in the mixtures of liver tissue digest and synthetic peptides was 
performed by nanoLC-ESI-ETD-HCD analysis. In figure 5, the chromatograms obtained for the 
different mixtures for “control-18” are shown. In figure 5A, the top chromatogram corresponds 
to the trypsin digest of liver tissue mixed with TFA, showing the retention time of peptide 
with ?xHyp. A zoom-in of the MS3 mass spectra is shown in figure 5C, this spectrum shows the 
characteristic peak m/z 454 and low intensity for m/z 400, therefore matching with the mass 
spectrum of GLH-4Hyp. In addition, the retention time of GLH-4Hyp (bottom chromatogram) 
overlaps with the peptide present in the digest, while GLH-3Hyp elutes 0.5 min later. That 
GLH-3Hyp and GLH-4Hyp have such different retention times comes as a surprise to us and 
this finding alone allows differentiation of GLH-3Hyp and GLH-4Hyp. Hydroxylation of 
?xHyp is not complete, hence we also observe the peptide containing unmodified proline. 
Retention times of GLH-Pro and the peptide originating from the digest containing Pro are 
identical. The other samples analyzed (Control-6, CRLM-18, and CRLM-6) gave similar results 
as shown in figure 5.
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Figure 5. Identification of ?xHyp in sample control-18 based on LC retention time differences and MS3 
fragmentation. Part A) and B) show retention times based on extracted ion chromatography for m/z 
498.57 and m/z 493.24, respectively, whereby chromatograms in B) originate from the same samples as 
A). The following peptides are seen in A) GLH-?xHyp (tR = 13.49 min), GLH-3Hyp (tR = 13.96 min), and GLH-
4Hyp (tR = 13.47 min), and in B) GLH-Pro (tR = 15.11 min). C) Zoom-in of the MS
3 mass spectra belonging to 
peptide present in the digest containing ?xHyp, top chromatogram in A). 
DISCUSSION
We conclude that the unknown ?xHyp at position 584 in COL1A2 is 4Hyp. We do not have any 
evidence for 3Hyp to be present at the Xaa position; however we cannot exclude the possibility 
that a small amount of 3Hyp is present below the detection limit. To prevent confusion with 
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respect to the nomenclature of collagen PTMs, we propose to address 4Hyp at the Xaa position 
as 4xHyp. The identification of in vivo 4xHyp is based on both retention time differences 
and mass spectrometry analysis. We have validated the proposed fragmentation scheme by 
calculating, with an ab initio method, the energy required for the observed fragmentations. 
We consider the required energy as relatively low, considering that the dissociation of a 
carbon-carbon bond requires about 350 kJ/mol. Therefore, HCD readily activates the further 
dissociation of the ring-opened structure.
Since we showed the identification of 4xHyp only in one position as a proof of principle, 
we cannot conclude that all 45 known positions of ?xHyp are 4xHyp. Hydroxyproline is 
not exclusively present in collagen and also occurs in other proteins. Spahr et al. describes 
the presence of hydroxyproline in a GGGGP linker of an FC-fusion protein.[323] However, 
the identity 3- or 4-hydroxyproline remains unknown. Zhou et al. report 562 sites in 272 
proteins in HeLa cells were hydroxyproline is present.[324] Zhou et al. assume that the 
found hydroxyprolines are 4-hydroxyprolines, but no evidence is provided with respect 
to the identity of the hydroxyprolines. The described method can also be used to identify 
3- or 4-hydroxyproline in non-collagen proteins. In collagen, sequence commonalities are 
observed between different locations, tissue types, and organisms which make it likely 
that all ?xHyp are in fact 4xHyp. Collagen type IV is a possible exception, where glutamine 
instead of alanine is dominantly present at position 1. The known enzyme substrate[304] for 
prolyl 4-hydroxylase does not match these sequence commonalities and this indicates the 
presence of an unknown substrate for prolyl 4-hydroxylase or an unknown substrate for a 
not yet identified enzyme with this function. This could be investigated by offering a guest 
peptide containing Gly-Pro-Ala or Gly-Pro-Gln to prolyl 4-hydroxylase or liver lysates. Such an 
experiment was previously performed to study the effect of an amino acid at the Xaa position 
on the hydroxylation rate of proline into 4Hyp.[79] It was shown that an amino acid at the 
Xaa position has a major influence on the hydroxylation rate of proline at the Yaa position. 
Furthermore, modification of proline into 4xHyp is not observed in all COL1A2 molecules, in 
liver tissue the peptide containing unmodified proline is present at a significant higher level 
than the peptide containing 4xHyp. In CRLM tissue, the unmodified peptide is at significant 
higher levels present, which is not surprising because COL1A2 is strongly upregulated 
in CRLM compared to liver tissue (p= 9.4*10-10, fold change = 1.7) [26]. However, the peptide 
containing 4xHyp did increase significantly but not as strong as the peptide lacking ?xHyp. 
The calculated ratio between peptides containing 4xHyp and lacking 4xHyp is significantly 
different between CRLM and liver tissue, and this clearly distinguishes the adjacent liver 
from CRLM tissue.
The role of 4xHyp is unknown, although it has been shown that 4Hyp stabilizes the triple 
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helix [306]. In general, 4Hyp provides the required thermal stability to form a triple helix at 
body temperature by forming hydrogen bonds with its surroundings. However, an amino 
acid at the Yaa position has less interaction with its surroundings than an amino acid at the 
Xaa position where 4xHyp is located [325]. Therefore, a different stabilization effect can be 
expected. Further investigation is required to identify the role of 4xHyp in stabilizing the 
triple helix. 
The R configuration of the hydroxyl group in 4Hyp, included in the (2S,4R)-4-hydroxyproline 
moiety, is crucial for the stabilization of the triple helix [326]. However, it is unknown how 
4xHyp is formed, so we cannot assume that the configuration is similar to 4Hyp. Further 
research is required to determine the configuration of the hydroxyl group. 
The understanding of collagen PTMs is crucial for the understanding of the role of collagen 
in, among others, tissue formation, cell attachment, tissue support, tumor proliferation, 
and handling physical stress. The identification of ?xHyp as 4xHyp at position 584 in COL1A2 
brings us another step closer to the understanding of collagen PTMs and possibilities to 
apply this knowledge for understanding tumor metastasis and generate possibilities for 
diagnosis of cancer.
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GENERAL DISCUSSION
In cancerous tissue, collagen can be strongly modified at the molecular level as well as at 
the supramolecular level. Changes in the extracellular matrix, of which collagen is a major 
component, may stimulate tumor proliferation and even induce tumorigenesis.[24, 269, 327-330] The 
opposite is also true: collagen may inhibit tumor cells, and even prevent cells from becoming 
malignent.[24, 269] Collagen changes have mostly been studied at the protein or supramolecular 
structure level but specific studies including posttranslational modifications in different 
types of cancer are lacking. Nonetheless, changes at the posttranslational modification 
level will strongly affect the supramolecular structure organization; leading to dysregulated 
collagen, as described in Chapter 2. For example, 3-hydroxyproline, 4-hydroxyproline, and 
glycosylation influence triple helix formation, inter-triple helix interaction, and cross-
linking. On top of that, a change of the triple helix composition can have severe consequences. 
Studies have shown that collagen type 1 homotrimers are immune for MMPs and enhance 
tumor mobility[331], whereas the loss of specific collagen type IV alpha chains correlates with 
tumor differentiation.[332] Within a tumor large differences in collagen that correlate with 
different tumor characteristics maybe be present.[333]
Collagen is affected in CRLM [152, 334], and this is reflected in serum [178, 335] and urine [11, 12]. The 
combination of collagen in urine and carcinoembryonic antigen (CEA) in serum showed to 
be very promising to detect CRLM.[11, 12] CEA is already used in the detection of CRLM, however 
the sensitivity (68%) is too low.[14]The aim of this thesis is to improve analysis of collagen NOPs 
in urine and combined with serum CEA in order to detect CRLM. The advantage of urine is 
that it can be obtained non-invasively. Larger volumes of urine can be easily collected also 
outside the hospital. In addition, there is no need for imaging in the hospital, With the use of 
urine, analysis can be performed at a higher frequency than with the current techniques with 
the advantage of potentially detecting metastasis at an earlier stage.
We describe the possibility of detecting CRLM with a high sensitivity and specificity through 
a combination of a collagen NOP, GNDGARGSDGQPGPP(-OH)GP(-OH)P(-OH)GTAGFP(-OH)
GSP(-OH)GAK(-OH)GEVGP, in urine and CEA in serum. Besides GND, also other collagen 
NOPs are significantly different between urine of healthy controls and patients with CRLM. 
Collagen NOPs might originate from different processes including: 1) collagen turnover 
inside the tumor; 2) collagen turnover in healthy tissue in close proximity of the tumor; or 
3) a more unlikely coincidental non-related tumor process. The following checks should be 
performed to confirm that collagen NOPs selected for validation are related to CRLM: 1) The 
collagen NOP and corresponding hydroxylation pattern should be differentially present in 
CRLM and control tissue; and 2) the collagen NOP should belong to a collagen type that is 
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significantly different between healthy and tumor tissue. The presence of these NOPs in CRLM 
tissue does not prove that the NOP is caused by the tumor, but shows at least an association.
In this thesis we have shown that most collagen types appeared to be affected by CRLM: the 
collagen abundance is significantly upregulated in CRLM compared to liver tissue; specific 
collagen type levels are more comparable to colon tissue than to liver tissue; and the degree 
of collagen hydroxylation in cancer is significantly lower than that in normal tissue. In 
addition, we identified 4-hydroxyproline at the exceptional Xaa-position (4xHyp) instead 
of at the Yaa position. Collagen affected by CRLM contained also less 4xHyp compared to 
healthy liver tissue. 
A proper understanding of the collagen composition and hydroxylation mechanisms in 
CRLM is important and could be extended to other types of cancer. For diagnostic purposes, 
it would be interesting to study, for example, the change in collagen composition and the 
degree of hydroxylation at the transition zone between CRLM and healthy adjacent liver tissue. 
Especially studying differences between the various known growth patterns observed in 
CRLM is of interest.[333] Technically, this could be performed by selecting tissue corresponding 
to the different growth patterns with laser microdissection microscopy, followed by mass 
spectrometry analysis. In addition, electron microscopy can aid in visualizing the effects of 
CRLM on the supramolecular organization of collagen.
PERSPECTIVE
We have demonstrated that urine is a very promising body fluid to detect CRLM based on 
collagen NOPs. Currently, the method described in Chapter 3 has a similar or an even better 
sensitivity and specificity as the currently-used techniques. We foresee that detection of CRLM 
based on collagen NOPs in urine will replace present techniques as first line of detection. 
Most ideally, an improvement will be made by which CRLM detection can be solely based on 
urine instead of a combination with serum. 
Maxim et al. give an overview of 142 different screening tests for various diseases; the overall 
sensitivity is 94.9% (median; interquartile range (IQR) [85.1-99.1]), and the specificity is 80.1% 
(median; IQR [67.4-89.5]).[336] The sensitivity was higher than the specificity in almost three-
quarters of the screening tests. To prevent false negatives, high sensitivity is favored over a 
high specificity. The test we have developed is intended for patients at risk and is therefore 
not necessarily a population screening test; therefore, a somewhat lower specificity can be 
acceptable for these patients at risk. 
To reach levels of more than 95% sensitivity and specificity, additional collagen NOPs in urine 
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need to be screened for their value as molecular marker. We reported over 100 significant 
different collagen NOPs, and, so far, only three peptides (AGP, GPP, and GND) have been 
validated. This implicates that still many promising candidates are left to be tested. Candidate 
NOPs should be selected on the basis of the two criteria described above, and a third criteria 
should be added: the NOP should have a low degree of hydroxylation, because collagen 
hydroxylation is significantly downregulated in tumor tissue. Easy screening methods to tests 
all these molecules should be developed to reach most optimal sensitivities and specificities.
 
Collagen NOPs in urine of patients with CRLM, which have a lower hydroxylation pattern 
than in healthy tissue, will revert to normal levels after tumor resection. Up to 70% of the 
liver can be removed; the liver can regenerate and will do so over the course of a year.[337] 
Surgery will cause scarring of tissue, which takes more than a year to heal.[338] Collagen is 
strongly involved in the processes of regeneration and tumor formation, which results in 
higher collagen turnover and remodeling. It is essential to get longitudinal data of patients 
at risk; with the information deduced from these data we might improve the sensitivity and 
specificity of the test.
 
The European Union supports our COLO-MET project, which allows us to continue 
investigating collagen NOPs in urine to detect CRLM, and to bring the test a step closer to 
clinical implementation (https://www.eithealth.eu/en_US/colo-met ). We hope that we can 
demonstrate that an urine-based detection method is able to detect CRLM at an earlier stage 
than the currently used techniques. Earlier detection would benefit the patient, because 
smaller tumor size and smaller number of tumors may affect decission making in the 
management of a patient developing CRLM.[339-341] 
A better insight in tumor biology of collagen may help to optimize treatment strategies, thus 
improving the outcome for people with CRLM. 
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SUMMARY
The research described in this thesis focusses on the detection of collagen natural occurring 
peptides (NOPs) in urine in order to improve detection of colorectal liver metastasis (CRLM). 
In addition, to understand the observed differences in urine levels of NOPS, collagen was 
studied in organs affected by CRLM. 
Chapter 2 contains a review of collagen and collagen analysis with mass spectrometry. 
Collagen is a family of 45 different proteins, called alpha chains, which are divided over 28 
collagen types. Each collagen type consists of up to six different unique alpha chains. Alpha-
chains contain a region (triple helical region) in the primary amino acid sequence that 
consists of the repeating unit [-Gly-Xaa-Yaa-]n, wherein Xaa and Yaa can be different amino 
acids. The triple helical region makes it possible for three collagen alpha chains to form a 
triple helix. Another characteristic of collagen is the extensive posttranslational modification 
(PTM) of proline and lysine. PTMs are crucial for triple helix formation and the formation 
of large supramolecular structures. Mass spectrometry is a versatile technique that can be 
used to analyze collagen, more specifically to analyze the amino acid sequence, proline and 
lysine PTMs, as well as the general composition in various body fluids (e.g. serum, urine) and 
tissue types (e.g. liver, bone). Mass spectrometry can also be used to quantitatively measure 
collagen concentrations in various diseases. 
 
In Chapter 3 we described the identification and validation of collagen NOPs in urine as a way 
to improve the detection of CRLM. Collagen NOPs were identified in urine with a standard 
bottom-up proteomics approach. The most distinctive NOPs were selected and validated 
with a targeted mass spectrometry method. A newly validated collagen NOP in combination 
with carcinoembryonic antigen levels in blood formed a new molecular marker panel with 
better predictive power than the currently used techniques.
In Chapter 4 we described the compositional difference of collagen between liver and CRLM 
tissue. In general, collagen is significantly upregulated in CRLM compared to liver tissue. Also 
proteins related to collagen synthesis are mostly upregulated. The composition of collagen 
in CRLM tissue differs from that in liver tissue. The abundance of collagen types 10, 12, 14, and 
15 is more similar to colon tissue than to liver tissue, and could have migrated via the primary 
tumor (colorectal cancer, CRC) to CRLM.
In the data presented in Chapter 4, we observed – in contrast to a higher abundance 
of collagen – a decrease in the hydroxylation degree of collagen in CRLM compared to 
liver tissue. In Chapter 5 we analyzed, in more detail, the degree of collagen alpha-1(I) 
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hydroxylation in colon, CRC, liver, and CRLM tissues. We confirmed the significant decrease 
in the hydroxylation degree of collagen alpha-1(I) in CRLM and CRC, compared to liver and 
colon tissue, respectively. Furthermore, it appeared that within patients’ healthy tissue, 
collagen alpha-1(I) is present with different hydroxylation forms. The degree of hydroxylation 
of collagen alpha-1(I) in colon and liver tissue did not differ. However, locally significant 
differences were present. In addition, we showed that peptides with a specific degree of 
hydroxylation that are significantly different in tissue, can be differentially present in urine.
In the data presented in Chapter 4, an unexpected proline PTM was observed at the Xaa 
position. In literature, multiple locations have been described in which this unexpected 
proline PTM occurs. However, the identity of this proline PTM remained unknown. Chapter 
6 describes the proof-of-principle identification of 4-hydroxyproline at position 584 
(4xHyp) in collagen alpha-2(I). We have developed a mass spectrometry method which can 
differentiate between 3-hydroxyproline and 4-hydroxyproline. This method consists of serial 
fragmentation of a peptide containing 4xHyp with electron transfer dissociation (ETD) and 
higher-energy collisional dissociation (HCD). First the proline backbone is broken with 
ETD, followed by complete fragmentation of the proline ring with HCD. 4xHyp was observed 
both in liver tissue and in CRLM tissue. Similar levels of 4xHyp are present in both tissue 
types, while the overall collagen content in CRLM was strongly increased. Therefore, the ratio 
between collagen with and without 4xHyp was lower in CRLM tissue.
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SAMENVATTING
Het onderzoek beschreven in dit proefschrift betreft de detectie van natuurlijk voorkomende 
collageenpeptiden (collageen-NOPs) in urine, waarmee de detectie van colorectale lever 
metastase (CRLM) kan worden verbeterd. Om de verschillen in collageen-NOPs in urine 
te kunnen begrijpen, hebben we ook collageen bestudeerd in organen waar CRLM zich 
manifesteert.
 
In Hoofdstuk 2 wordt een overzicht gegeven van de eigenschappen van collageen, en de 
analyse van collageen met behulp van massaspectrometrie. Collageen is een familie van 
45 verschillende eiwitten, alpha chains genaamd die onderverdeeld kunnen worden in 
28 typen. Elk collageen type kan bestaan uit 1 t/m 6 verschillende unieke alpha chains. 
In de aminozuursequentie van elke alpha-chain zit een gebied dat bestaat uit [-Gly-Xaa-
Yaa-]n, waarbij Xaa en Yaa verschillende aminozuren kunnen zijn. Dit gebied maakt het 
mogelijk dat drie alpha chains samen een triple helix kunnen vormen. De uitgebreide 
posttranslationele modificaties (PTMs) van lysine en proline vormen een ander kenmerk van 
collageen. PTMs zijn cruciaal voor de vorming van collageen triple helices, en de vorming 
van grote supramoleculaire structuren. Massaspectrometrie is een veelzijdige techniek 
die uitermate geschikt is om collageen op moleculaire schaal te analyseren. Bijvoorbeeld: 
de aminozuursequentie, proline en lysine PTMS, de samenstelling in verschillende 
lichaamsvloeistoffen (bijv. urine en serum), en de samenstelling in verschillende soorten 
weefsels (bijv. lever, darm, tumor). Massaspectrometrie kan ook gebruikt worden voor de 
kwantitatieve analyse van collageen, al dan niet in verband met verschillende ziektes.
 
In Hoofdstuk 3 beschrijven we de identificatie en validatie van collageen-NOPs in urine om 
de detectie van CRLM te verbeteren. De collageen-NOPs zijn geïdentificeerd door middel 
van een standaard bottom-up proteomicsmethode. De meest onderscheidende NOPs zijn 
geselecteerd voor verdere validatie met een kwantitatieve massaspectrometriemethode. Een 
gevalideerd collageen-NOP gecombineerd met carcino-embryonaal antigen (CEA) in serum 
vormt het nieuwe moleculaire marker panel – met een betere voorspellende waarde dan 
verkregen met de technieken die momenteel in het ziekenhuis worden gebruikt.
 
In Hoofdstuk 4 beschrijven we het verschil in de samenstelling van collageen tussen CRLM 
en leverweefsel. In het algemeen is collageen significant verhoogd in CRLM- vergeleken 
met leverweefsel. Ook zijn de eiwitten die gerelateerd zijn aan de vorming van collageen 
verhoogd. Collageen in CRLM-weefsel heeft een andere samenstelling dan collageen in 
leverweefsel. De expressieniveaus van collageen type 10, 12, 14, en 15 lijken sterker op darm- 
dan op leverweefsel. Het is mogelijk dat de expressie van deze collageen types via de primaire 
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tumor (CRC) is gemigreerd naar CRLM.
 
In de data verzameld in Hoofdstuk 4 hebben we ontdekt dat, in tegenstelling tot de 
verhoogde expressie van collageen, de mate van collageenhydroxylatie verlaagd is in CRLM-
weefsel ten opzichte van leverweefsel. In Hoofdstuk 5 hebben we de mate van collageen 
alpha-1(I) hydroxylatie nader onderzocht in darm-, lever-, CRLM-, en CRC-weefsel. Hieruit 
volgde dat collageen inderdaad in mindere mate gehydroxyleerd is in CRLM- en CRC-weefsel 
vergeleken met respectievelijk lever- en darmweefsel. Uit onderzoek bleek dat zelfs binnen 
weefsel van eenzelfde patiënt meerdere hydroxylatievormen van collageen voorkomen. Over 
het geheel genomen verschilt de mate van hydroxylatie niet tussen darm- en leverweefsel, 
maar op bepaalde plaatsen zijn wel significante verschillen aanwezig. Vervolgens laten we 
ook zien dat het mogelijk is de verschillen die in urine gezien worden te koppelen aan het 
verschil in de mate van collageenhydroxylatie tussen CRLM- en leverweefsel.
 
In de data verzameld in Hoofdstuk 4 hebben we een onbekende proline PTM gevonden op de 
Xaa-positie. In de literatuur is de aanwezigheid hiervan op verschillende posities meerdere 
keren beschreven, maar de identiteit was tot nu toe onbekend. In Hoofdstuk 6 laten we zien 
dat het mogelijk was deze te identificeren als 4-hydroxyproline (4xHyp) in collageen alpha-
2(I) positie 584. We hebben een massaspectrometriemethode ontwikkeld die onderscheid 
kan maken tussen 3- en 4-hydroxyproline. Deze methode bestaat uit het fragmenteren met 
behulp van ETD en HCD fragmentatie technieken. Met ETD wordt de backbone van proline 
gebroken, en verdere fragmentatie vindt plaats door middel van HCD. 4xHyp is aanwezig in 
zowel lever- als in CRLM-weefsel. Beide weefsels bevatten ongeveer evenveel 4xHyp, maar 
collageen is sterk verhoogd in CRLM-weefsel. Hierdoor was de ratio tussen collageen dat wel 
4xHyp bevat en collageen dat niet 4xHyp bevat significant lager in CRLM-weefsel.
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